Breaking News

Tuesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	Compugen granted U.S. patent for COM701 antibody » 07:10 01/18/22 01/18 07:10 01/18/22 07:10 CGEN Compugen $3.88 / +0.04 (+1.04%) Compugen has been granted… Compugen has been granted a new patent by the USPTO covering method of use for COM701, Compugen's potential first-in-class therapeutic antibody targeting PVRIG, or back-up anti-PVRIG antibody, in triple combination with any anti-PD-1 and any anti-TIGIT antibody for the treatment of cancer. The patent augments previously issued patents by expanding and protecting the use of COM701 for treating cancer patients, to include the triplet combination of COM701 with any anti-PD-1 antibody and any anti-TIGIT antibody. The patent is expected to expire no earlier than August 2037 in the U.S. ShowHide Related Items >><< Company News Earnings On The Fly CGEN Compugen $3.88 / +0.04 (+1.04%) 12/09/21 Compugen reports results from trial of COM701 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study CGEN Compugen $3.88 / +0.04 (+1.04%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) CGEN Compugen $3.88 / +0.04 (+1.04%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday

Over a month ago
Hot Stocks	Compugen reports results from trial of COM701 » 07:05 12/09/21 12/09 07:05 12/09/21 07:05 CGEN Compugen $4.62 / +0.2 (+4.53%) Compugen announced the… Compugen announced the presentation of preliminary translational data from patient biopsies demonstrating immune activation in the tumor microenvironment after treatment with COM701, Compugen's potentially first-in-class anti-PVRIG antibody, as a monotherapy and in combination with nivolumab at the TIGIT Therapies Digital Summit. "These translational data are exciting as they represent the first demonstration of immune activation in the TME of patients who have been treated with COM701 monotherapy or in combination with nivolumab and add to previous data showing immune activation in peripheral blood taken from treated patients," said Eran Ophir, Ph.D., Vice President of Research and Drug Discovery at Compugen. "In addition, we are encouraged by the observed increases in clonal expansion of T cells, immune infiltration and immune activation in an MSS-CRC patient with a confirmed response after COM701 and nivolumab combination therapy given this is an indication that is unlikely to respond to PD-1 blockade. These results are consistent with our earlier findings supporting PVRIG pathway involvement in early differentiation memory T cell priming and activation and provide important evidence of immune modulation at the location critical for efficacy, the tumor site." ShowHide Related Items >><< Company News Earnings Periodicals On The Fly CGEN Compugen $4.62 / +0.2 (+4.53%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial CGEN Compugen $4.62 / +0.2 (+4.53%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) CGEN Compugen $4.62 / +0.2 (+4.53%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says CGEN Compugen $4.62 / +0.2 (+4.53%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday
Conference/Events	JMP Securities to hold a virtual summit » 04:55 12/07/21 12/07 04:55 12/07/21 04:55 ALLO Allogene Therapeutics $17.19 / -0.45 (-2.55%) , BCYC Bicycle Therapeutics $50.35 / -2.24 (-4.26%) , BCAB BioAtla $22.46 / +0.105 (+0.47%) , BCRX BioCryst $11.18 / -0.275 (-2.40%) , BPMC Blueprint Medicines $95.36 / +1.105 (+1.17%) , CLLS Cellectis $8.08 / -0.18 (-2.18%) , CGEN Compugen $4.20 / +0.03 (+0.72%) , CTIC CTI BioPharma $1.68 / +0.075 (+4.69%) , CUE Cue Biopharma $10.94 / -0.45 (-3.95%) , CVAC CureVac $40.76 / -2.91 (-6.66%) , DCPH Deciphera $8.03 / +0.03 (+0.38%) , EFTR eFfector Therapeutics $7.44 / +1.7 (+29.62%) , GMDA Gamida Cell $2.34 / -0.015 (-0.64%) , HOOK Hookipa Pharma $2.94 / + (+0.00%) , INBX Inhibrx $36.50 / -0.49 (-1.32%) , IOVA Iovance Biotherapeutics $16.93 / +0.37 (+2.23%) , KURA Kura Oncology $12.41 / -0.05 (-0.40%) , MGN Mines Management $1.13 / + (+0.00%) , MOR MorphoSys $9.07 / -0.39 (-4.12%) , NXTC NextCure $5.84 / +0.1 (+1.74%) , PTGX Protagonist Therapeutics $32.77 / +0.43 (+1.33%) , PRTA Prothena $44.06 / -2.565 (-5.50%) , SPPI Spectrum $1.37 / -0.005 (-0.36%) , SYRS Syros Pharmaceuticals $3.96 / +0.39 (+10.92%) , VOR Vor Biopharma $13.15 / +0.5 (+3.95%) Hematology & Oncology… Hematology & Oncology Virtual Summit to be held on December 6-7.Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VOR SYRS SPPI PTGX PRTA NXTC MOR KURA IOVA INBX HOOK GMDA EFTR DCPH CVAC CUE CTIC CLLS CGEN BPMC BCYC BCRX ALLO VOR Vor Biopharma $13.15 / +0.5 (+3.95%) 10/12/21 Vor Biopharma appoints Veit Schmelmer as SVP, program and alliance management 09/10/21 Vor Biopharma receives fast track designation for VOR33 from FDA 09/09/21 Vor Biopharma's VOR33 granted FDA Fast Track designation for AML 07/09/21 Vor Biopharma enters collaboration Janssen Biotech SYRS Syros Pharmaceuticals $3.96 / +0.39 (+10.92%) 10/12/21 Syros Pharmaceuticals appoints Jason Haas CFO 09/29/21 Syros reports 1st patient in dose confirmation study of ATO oral for APL 09/27/21 Syros Pharmaceuticals appointment of Conley Chee as Chief Commercial Officer 09/20/21 Syros Pharmaceuticals presents new data from Phase 1 trial of SY-5609 SPPI Spectrum $1.37 / -0.005 (-0.36%) 12/06/21 Spectrum submits new drug application for poziotinib to FDA 12/01/21 Spectrum COO Tom Riga named next president, CEO 09/19/21 Spectrum presents results from Cohort 4 of ZENITH20 clinical trial 08/06/21 Spectrum receives CRL from FDA citing deficiencies in Rolontis BLA PTGX Protagonist Therapeutics $32.77 / +0.43 (+1.33%) 12/02/21 Protagonist Therapeutics announces selection of PN-235 into Phase 2 development 11/15/21 Protagonist Therapeutics announces results from Phase 2a study of rusfertide 10/26/21 Protagonist Therapeutics earns $7.5M milestone payment from Janssen Biotech 10/11/21 Protagonist Therapeutics: FDA removes full clinical hold on rusfertide program PRTA Prothena $44.06 / -2.565 (-5.50%) 10/15/21 Prothena appoints Chris Bailey as president, Proterra Powered & Energy 10/13/21 Massachusetts electric school bus helps power electricity grid 10/01/21 Prothena names Brandon Smith as COO 07/26/21 Prothena presents new data from Alzheimer's portfolio at AAIC NXTC NextCure $5.84 / +0.1 (+1.74%) 11/14/21 NextCure provides updates on NC318, NC410 candidates at SITC Annual Meeting 10/19/21 NextCure announces three new members of its SAB 10/04/21 NextCure appoints Ellen Feigal, Anne Borgman to board of directors 07/06/21 NextCure initiates NC762 trial MOR MorphoSys $9.07 / -0.39 (-4.12%) 11/04/21 MorphoSys presents interim results from M-PLACE study with felzartamab 11/02/21 MorphoSys reports Q3 Monjuvi U.S. sales of $22M 08/26/21 MorphoSys spikes 6% after EC grants conditional MA for Minjuvi combo treatment 08/26/21 MorphoSys, Incyte get EC conditional MA for Minjuvi-lenalidomide combo for DLBCL KURA Kura Oncology $12.41 / -0.05 (-0.40%) 11/24/21 Kura Oncology's Phase 1b study of AML candidate placed on hold by FDA 10/18/21 Kura Oncology appoints Teresa Blair as Chief Legal Officer 07/29/21 Kura Oncology appoints Helen Collins to board of directors 07/06/21 Kura Oncology and Novartis announce clinical collaboration IOVA Iovance Biotherapeutics $16.93 / +0.37 (+2.23%) 11/14/21 Iovance announces data for Lifileucel in combination with Pembrolizumab 11/12/21 Iovance Biotherapeutics announces clinical data for LN-145 at SITC 2021 meeting 11/09/21 Iovance Biotherapeutics announces clinical data from TIL cell therapy 09/23/21 Iovance Biotherapeutics initiates clinical supply of TIL cell therapy INBX Inhibrx $36.50 / -0.49 (-1.32%) 12/01/21 Inhibrx granted FDA orphan-drug designation for INBRX-109 11/24/21 Inhibrx treatment of Chondrosarcoma granted FDA orphan designation 10/12/21 Inhibrx reports Phase 1 results from trial of INBRX-101 06/21/21 Inhibrx initiates potential registration-enabling Phase 2 study of INBRX-109 HOOK Hookipa Pharma $2.94 / + (+0.00%) 11/09/21 Hookipa Pharma advances HB-200 program to Phase 2 10/14/21 Hookipa Pharma announces publication on arenaviral immunotherapies in cancer 09/15/21 Hookipa announces collaboration with Merck to evaluate HB-200 with KEYTRUDA 08/12/21 Hookipa Pharma provides update on upcoming milestones GMDA Gamida Cell $2.34 / -0.015 (-0.64%) 11/15/21 Gamida Cell reports Q3 EPS ($1.18), consensus (48c) 11/11/21 Gamida Cell delays omidubicel BLA submission to FDA till 1H22 08/09/21 Tempest Therapeutics appoints Ronit Simantov to board of directors 08/02/21 Enlivex hires Tzvi Palash as Project Lead to design, construct new plant EFTR eFfector Therapeutics $7.44 / +1.7 (+29.62%) 11/24/21 eFfector Therapeutics announces publication of zotatifin preclinical data 10/07/21 eFfector Therapeutics presents positive zotatifin data in animal models of TNBC 09/09/21 eFFECTOR Therapeutics Inc trading resumes 09/09/21 eFFECTOR Therapeutics Inc trading halted, volatility trading pause DCPH Deciphera $8.03 / +0.03 (+0.38%) 11/30/21 Deciphera Pharmaceuticals trading resumes 11/30/21 Deciphera reports corporate restructuring, discontinuation of rebastinib program 11/30/21 Deciphera Pharmaceuticals trading halted, news pending 11/22/21 Deciphera gets EC approval of Qinlock for 4th line GI stromal tumor CVAC CureVac $40.76 / -2.91 (-6.66%) 11/18/21 CureVac publishes preclinical data of 2nd generation COVID candidate CV2CoV 10/15/21 CureVac holder dievini seeks registration for resale of shares 10/12/21 CureVac falls over 14% after withdrawing CVnCoV COVID vaccine candidate 10/12/21 CureVac to withdraw CVnCoV COVID-19 vaccine candidate, focus on mRNA vaccine CUE Cue Biopharma $10.94 / -0.45 (-3.95%) 11/12/21 Cue Biopharma presents updated data from CUE-101 program 09/28/21 Cue Biopharma announces publication on immunotherapeutic platforms 09/21/21 Cue Biopharma granted U.S. patents on CUE-101 08/03/21 Cue Biopharma to present corporate update at BTIG conference CTIC CTI BioPharma $1.68 / +0.075 (+4.69%) 11/30/21 CTI BioPharma announces extension of FDA review period for pacritinib NDA 10/01/21 CTI BioPharma PRE-VENT pacritinib trial does not meet primary endpoint 08/25/21 CTI BioPharma and DRI Healthcare Trust enter funding transaction for up to $135M CLLS Cellectis $8.08 / -0.18 (-2.18%) 11/18/21 Cellectis, Cytovia expand gene-edited NK cells partnership in China 11/12/21 Cellectis presents preclinical data on UCARTMESO 11/04/21 Cellectis announces release of abstracts at ASH showcase 10/19/21 Cellectis to present two presentations at the ESGCT CGEN Compugen $4.20 / +0.03 (+0.72%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial BPMC Blueprint Medicines $95.36 / +1.105 (+1.17%) 12/06/21 Blueprint Medicines: Nature Medicine publishes results from AYVAKIT studies 11/29/21 Blueprint Medicines to acquire Lengo Therapeutics for $250M in cash 11/09/21 Blueprint Medicines and Zai Lab announces collaboration and license agreement 07/28/21 Blueprint Medicines enters research collaboration with MD Anderson for BLU-222 BCYC Bicycle Therapeutics $50.35 / -2.24 (-4.26%) 11/04/21 Bicycle Therapeutics: First patient dosed in Phase I/II trial of BT7480 10/26/21 Bicycle Therapeutics, Genentech team to develop immuno-oncology therapies 10/07/21 Bicycle Therapeutics reverses higher, up 4% after volatility halt 10/07/21 Bicycle Therapeutics down 20% after data on BT5528, BT8009 trials BCRX BioCryst $11.18 / -0.275 (-2.40%) 12/03/21 BioCryst reports inducement grants under Nasdaq listing rule 12/02/21 Praxis Precision Medicines appoints Megan Sniecinski as CBO 11/29/21 BioCryst begins patient enrollment in REDEEM-2 trial of BCX9930 11/24/21 BioCryst CFO buys 35K shares of common stock ALLO Allogene Therapeutics $17.19 / -0.45 (-2.55%) 12/01/21 Allogene announces call to review ALPHA, ALPHA2, UNIVERSAL data 11/04/21 Allogene Therapeutics to showcase clinical data at ASH annual meeting 10/07/21 Allogene Therapeutics trading resumes 10/07/21 Allogene says FDA put clinical hold on AlloCar T clinical trials ALLO BCYC BCAB BCRX BPMC CLLS CGEN CTIC CUE CVAC DCPH EFTR GMDA HOOK INBX IOVA KURA MGN MOR NXTC PTGX PRTA SPPI SYRS VOR ALLO Allogene Therapeutics $17.19 / -0.45 (-2.55%) 12/03/21 Canaccord Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord 10/19/21 Cowen Allogene Therapeutics assumed with an Outperform at Cowen 10/12/21 JMP Securities Allogene Therapeutics price target lowered to $27 from $53 at JMP Securities 10/08/21 Fly Intel: Top five analyst downgrades BCYC Bicycle Therapeutics $50.35 / -2.24 (-4.26%) 10/14/21 JMP Securities Bicycle Therapeutics price target raised to $85 from $53 at JMP Securities 10/11/21 Canaccord Bicycle Therapeutics price target raised to $60 from $40 at Canaccord 10/08/21 Oppenheimer Bicycle Therapeutics price target raised to $65 from $47 at Oppenheimer 10/08/21 B. Riley Bicycle Therapeutics price target raised to $72 from $56 at B. Riley BCAB BioAtla $22.46 / +0.105 (+0.47%) 10/14/21 BTIG BioAtla assumed with a Buy at BTIG 06/28/21 Roth Capital BioAtla initiated with a Buy at Roth Capital 05/04/21 Credit Suisse BioAtla assumed with an Outperform at Credit Suisse 05/04/21 JPMorgan BioAtla price target raised to $64 from $45 at JPMorgan BCRX BioCryst $11.18 / -0.275 (-2.40%) 11/22/21 Piper Sandler BioCryst financing lifts one of two overhangs, says Piper Sandler 11/04/21 Barclays BioCryst price target lowered to $17 from $21 at Barclays 11/03/21 Piper Sandler BioCryst earnings pullback a buying opportunity, says Piper Sandler 08/06/21 Jefferies BioCryst downgraded to Hold from Buy at Jefferies BPMC Blueprint Medicines $95.36 / +1.105 (+1.17%) 12/01/21 Raymond James Blueprint Medicines added to Analyst Current Favorites list at Raymond James 11/29/21 Stifel Stifel expects neutral reaction for Blueprint acquisition of Lengo Therapeutics 11/29/21 Piper Sandler Blueprint acquisition may surprise investors looking for buyout, says Piper 11/19/21 Morgan Stanley Blueprint Medicines assumed with an Equal Weight at Morgan Stanley CLLS Cellectis $8.08 / -0.18 (-2.18%) 11/30/21 JMP Securities Cellectis initiated with an Outperform at JMP Securities 11/08/21 William Blair Cellectis downgraded to Market Perform at William Blair on slow execution 11/08/21 William Blair Cellectis downgraded to Market Perform from Outperform at William Blair 10/08/21 Baird Baird cuts Cellectis to Neutral after partner Allogene's clinical hold CGEN Compugen $4.20 / +0.03 (+0.72%) CTIC CTI BioPharma $1.68 / +0.075 (+4.69%) 12/01/21 Lake Street CTI BioPharma delay creates buying opportunity, says Lake Street 10/04/21 Lake Street CTI BioPharma should be bought on weakness after PRE-VENT miss, says Lake Street 08/09/21 BTIG CTI BioPharma initiated with a Buy at BTIG 06/01/21 Lake Street CTI BioPharma price target raised to $15 from $13 at Lake Street CUE Cue Biopharma $10.94 / -0.45 (-3.95%) CVAC CureVac $40.76 / -2.91 (-6.66%) 10/22/21 Fly Intel: Top five analyst initiations 10/22/21 Deutsche Bank CureVac initiated with a Hold at Deutsche Bank 07/01/21 Berenberg CureVac COVID vaccine data may be enough for EU approval, says Berenberg 06/30/21 CureVac announces COVID vaccine candidate demonstrates 48% efficacy DCPH Deciphera $8.03 / +0.03 (+0.38%) 12/01/21 H.C. Wainwright Deciphera price target lowered to $15 from $25 at H.C. Wainwright 11/30/21 Piper Sandler Deciphera price target lowered to $11 from $14 at Piper Sandler 11/08/21 Barclays Deciphera downgraded to Equal Weight at Barclays after GIST trial miss 11/08/21 Canaccord Deciphera downgraded to Hold at Canaccord EFTR eFfector Therapeutics $7.44 / +1.7 (+29.62%) 11/08/21 Stifel eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism 11/08/21 Stifel eFfector Therapeutics upgraded to Buy from Hold at Stifel 10/12/21 Credit Suisse eFfector Therapeutics initiated with an Outperform at Credit Suisse 10/04/21 Mizuho eFfector Therapeutics initiated with a Buy at Mizuho GMDA Gamida Cell $2.34 / -0.015 (-0.64%) 11/16/21 H.C. Wainwright Gamida Cell price target lowered to $22 from $27 at H.C. Wainwright 11/16/21 Oppenheimer Gamida Cell price target lowered to $15 from $17 at Oppenheimer 11/15/21 Piper Sandler Gamida Cell price target lowered to $13 from $23 at Piper Sandler 11/01/21 Alliance Global Partners Gamida Cell initiated with a Buy at Alliance Global Partners HOOK Hookipa Pharma $2.94 / + (+0.00%) 11/12/21 Morgan Stanley Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update 11/12/21 Morgan Stanley Hookipa Pharma downgraded to Equal Weight from Overweight at Morgan Stanley 11/11/21 H.C. Wainwright Hookipa Pharma price target lowered to $15 from $21 at H.C. Wainwright 11/10/21 JMP Securities Hookipa Pharma price target lowered to $11 from $25 at JMP Securities INBX Inhibrx $36.50 / -0.49 (-1.32%) 11/10/21 Credit Suisse Inhibrx price target raised to $53 from $44 at Credit Suisse 11/02/21 JMP Securities Inhibrx price target raised to $53 from $46 at JMP Securities 09/21/21 JMP Securities Inhibrx initiated with an Outperform at JMP Securities 04/26/21 Credit Suisse Inhibrx assumed with an Outperform at Credit Suisse IOVA Iovance Biotherapeutics $16.93 / +0.37 (+2.23%) 12/06/21 Cowen Iovance Biotherapeutics assumed with an Outperform at Cowen 11/15/21 Oppenheimer Iovance price target lowered to $31 from $38 at Oppenheimer 11/05/21 H.C. Wainwright Iovance Biotherapeutics price target lowered to $43 from $46 at H.C. Wainwright 11/05/21 Piper Sandler Iovance Biotherapeutics price target raised to $20 from $18 at Piper Sandler KURA Kura Oncology $12.41 / -0.05 (-0.40%) 11/26/21 Credit Suisse Kura Oncology price target lowered to $21 from $40 at Credit Suisse 11/24/21 H.C. Wainwright Kura Oncology price target lowered to $32 from $43 at H.C. Wainwright 05/04/21 Credit Suisse Kura Oncology assumed with an Outperform at Credit Suisse 04/26/21 Credit Suisse Kura Oncology assumed with an Outperform at Credit Suisse MGN Mines Management $1.13 / + (+0.00%) MOR MorphoSys $9.07 / -0.39 (-4.12%) 11/12/21 Morgan Stanley MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley 09/27/21 Citi MorphoSys downgraded to Neutral from Buy at Citi 09/13/21 Goldman Sachs MorphoSys reinstated with a Neutral at Goldman Sachs 09/02/21 Barclays MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays NXTC NextCure $5.84 / +0.1 (+1.74%) 11/05/21 Piper Sandler NextCure's Phase II NC318 study continuing weekly dosing, says Piper Sandler 08/08/21 Piper Sandler NextCure price target lowered to $21 from $26 at Piper Sandler 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist PTGX Protagonist Therapeutics $32.77 / +0.43 (+1.33%) 11/15/21 JMP Securities Protagonist Therapeutics price target raised to $70 from $60 at JMP Securities 11/04/21 Piper Sandler Piper 'pleasantly surprised' by Protagonist Therapeutics' ASH abstracts 10/13/21 JMP Securities Protagonist Therapeutics price target raised to $60 from $47 at JMP Securities 10/12/21 JPMorgan JPMorgan upgrades Protagonist after 'rapid' clinical hold removal PRTA Prothena $44.06 / -2.565 (-5.50%) 11/19/21 JMP Securities Prothena initiated with an Outperform at JMP Securities 09/30/21 RBC Capital Prothena price target raised to $82 from $59 at RBC Capital 09/27/21 Oppenheimer Prothena price target raised to $100 from $90 at Oppenheimer 09/20/21 Fox Advisors Prothena initiated with an Overweight at Fox Advisors SPPI Spectrum $1.37 / -0.005 (-0.36%) 08/18/21 B. Riley Spectrum price target lowered to $6 from $8 at B. Riley 06/01/21 H.C. Wainwright H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility SYRS Syros Pharmaceuticals $3.96 / +0.39 (+10.92%) 09/27/21 Roth Capital Veteran Chee coming aboard a positive for Syros, says Roth Capital 09/23/21 Roth Capital Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital 05/06/21 Piper Sandler Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler 03/05/21 Alliance Global Partners Syros price target lowered to $14 from $18 at Alliance Global Partners VOR Vor Biopharma $13.15 / +0.5 (+3.95%) 12/03/21 Baird Baird start Vor Biopharma with an Outperform ahead of AML data 12/02/21 Baird Vor Biopharma initiated with an Outperform at Baird 12/01/21 Oppenheimer Vor Biopharma initiated with an Outperform at Oppenheimer 10/19/21 JMP Securities Vor Biopharma initiated with an Outperform at JMP Securities VOR SYRS SPPI PTGX PRTA NXTC MOR KURA IOVA INBX HOOK GMDA EFTR DCPH CVAC CUE CTIC CLLS CGEN BPMC BCYC BCRX BCAB ALLO VOR Vor Biopharma $13.15 / +0.5 (+3.95%) 11/10/21 Vor Biopharma reports Q3 EPS (50c), consensus (62c) 08/09/21 Vor Biopharma reports Q2 EPS (50c), consensus (50c) SYRS Syros Pharmaceuticals $3.96 / +0.39 (+10.92%) 11/05/21 Syros Pharmaceuticals reports Q3 EPS (41c), consensus (44c) 08/05/21 Syros Pharmaceuticals reports Q2 EPS (36c), consensus (37c) SPPI Spectrum $1.37 / -0.005 (-0.36%) 11/10/21 Spectrum reports Q3 adjusted EPS (16c), consensus (28c) 08/12/21 Spectrum reports Q2 EPS (25c), consensus (25c) PTGX Protagonist Therapeutics $32.77 / +0.43 (+1.33%) 11/03/21 Protagonist Therapeutics reports Q3 EPS (70c), consensus (67c) 08/04/21 Protagonist Therapeutics reports Q2 EPS (69c), consensus (51c) PRTA Prothena $44.06 / -2.565 (-5.50%) 11/04/21 Prothena reports Q3 EPS $2.13, consensus $2.28 08/05/21 Prothena reports Q2 EPS 58c, consensus 55c NXTC NextCure $5.84 / +0.1 (+1.74%) 11/04/21 NextCure reports Q3 EPS (65c), consensus (67c) 08/05/21 NextCure reports Q2 EPS (65c), consensus (61c) MOR MorphoSys $9.07 / -0.39 (-4.12%) 07/26/21 MorphoSys narrows FY21 revenue view to EUR 155M-EUR180M from EUR 150M-EUR 200M KURA Kura Oncology $12.41 / -0.05 (-0.40%) 11/04/21 Kura Oncology reports Q3 EPS (50c), consensus (54C) 08/05/21 Kura Oncology reports Q2 EPS (51c), consensus (49c) IOVA Iovance Biotherapeutics $16.93 / +0.37 (+2.23%) 11/04/21 Iovance Biotherapeutics reports Q3 EPS (53c), consensus (53c) INBX Inhibrx $36.50 / -0.49 (-1.32%) 11/09/21 Inhibrx reports Q3 EPS (54c), consensus (57c) 08/09/21 Inhibrx reports Q2 EPS (55c), consensus (56c) HOOK Hookipa Pharma $2.94 / + (+0.00%) 11/10/21 Hookipa Pharma reports Q3 EPS (61c), consensus (52c) 08/12/21 Hookipa Pharma reports Q2 EPS (52c), consensus (53c) GMDA Gamida Cell $2.34 / -0.015 (-0.64%) 08/11/21 Gamida Cell reports Q2 EPS (76c), consensus (40c) EFTR eFfector Therapeutics $7.44 / +1.7 (+29.62%) 11/08/21 eFfector Therapeutics reports Q3 EPS 42c, consensus (25c) DCPH Deciphera $8.03 / +0.03 (+0.38%) 11/02/21 Deciphera Pharmaceuticals reports Q3 EPS ($1.37), consensus ($1.28) 08/03/21 Deciphera reports Q2 EPS ($1.21), consensus ($1.15) CVAC CureVac $40.76 / -2.91 (-6.66%) 08/16/21 CureVac reports Q2 revenue EUR 22.4M vs. EUR 34.5M a year ago CUE Cue Biopharma $10.94 / -0.45 (-3.95%) 08/17/21 Cue Biopharma reports Q2 EPS (33c), consensus (42c) CTIC CTI BioPharma $1.68 / +0.075 (+4.69%) 08/05/21 CTI BioPharma reports Q2 EPS (21c), consensus (21c) CLLS Cellectis $8.08 / -0.18 (-2.18%) 11/04/21 Cellectis reports Q3 EPS (82c) consensus (83c) 08/05/21 Cellectis reports Q2 EPS (80c), consensus (73c) CGEN Compugen $4.20 / +0.03 (+0.72%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) BPMC Blueprint Medicines $95.36 / +1.105 (+1.17%) 10/28/21 Blueprint Medicines sees 2021 revenue $170M-$180M, consensus $148.37M 10/28/21 Blueprint Medicines reports Q3 EPS ($2.00), consensus ($1.63) 07/29/21 Blueprint Medicines reports Q2 EPS ($1.86), consensus ($1.86) BCYC Bicycle Therapeutics $50.35 / -2.24 (-4.26%) 11/04/21 Bicycle Therapeutics reports Q3 EPS (59c), consensus (61c) 08/05/21 Bicycle Therapeutics reports Q2 EPS (74c), consensus (71c) BCRX BioCryst $11.18 / -0.275 (-2.40%) 11/03/21 BioCryst sees current cash runway funding operations into 2023 11/03/21 BioCryst sees FY21 ORLADEYO revenue to $115M-$120M 11/03/21 BioCryst reports Q3 EPS (33c), consensus (29c) 08/05/21 BioCryst reports Q2 EPS (24c), consensus (24c) BCAB BioAtla $22.46 / +0.105 (+0.47%) 08/13/21 BioAtla reports Q2 collaboration revenue $250,000 vs $190,000 last year ALLO Allogene Therapeutics $17.19 / -0.45 (-2.55%) 11/04/21 Allogene Therapeutics reports Q3 EPS (57c), consensus (56c) 08/04/21 Allogene Therapeutics reports Q2 EPS (53c), consensus (55c) 13 Oct 11 Aug 16 Jun 01 Apr 24 Mar 05 Feb 28 Jan 20 Jan 16 Dec 16 Dec 11 Dec 09 Dec 09 Dec SPPI CVAC CGEN SPPI Spectrum $1.37 / -0.005 (-0.36%) 12/02/21 Spectrum could be 'undervalued' if poziotinib hits in NSCLC, Dealreporter says CVAC CureVac $40.76 / -2.91 (-6.66%) 11/29/21 Judge halts Biden's health worker vaccine mandate in 10 states, The Hill says 07/01/21 CureVac plans to continue work on Covid-19 vaccine, CEO tells CNBC 06/08/21 E.U. health ministers meeting suggests CureVac COVID vaccine delayed, BI says CGEN Compugen $4.20 / +0.03 (+0.72%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says SPPI PTGX PRTA MOR KURA IOVA DCPH CVAC CTIC CGEN BCYC BCRX ALLO SPPI Spectrum $1.37 / -0.005 (-0.36%) 08/06/21 Wall Street in Fives - Must Read Lists for Friday 08/06/21 Wall Street in Fives - Must Read Lists at Midday 08/06/21 Fly Intel: Pre-market Movers PTGX Protagonist Therapeutics $32.77 / +0.43 (+1.33%) 10/11/21 Wall Street in Fives - Must Read Lists for Monday 09/17/21 Wall Street in Fives - Must Read Lists for Friday 09/17/21 Wall Street in Fives - Must Read Lists at Midday 09/17/21 Fly Intel: Pre-market Movers PRTA Prothena $44.06 / -2.565 (-5.50%) 07/12/21 Wall Street in Fives - Must Read Lists for Monday 07/12/21 Wall Street in Fives - Must Read Lists at Midday 06/07/21 Biotech shares rise as FDA approves Biogen's controversial Alzheimer's drug MOR MorphoSys $9.07 / -0.39 (-4.12%) 08/26/21 Fly Intel: After-Hours Movers 07/26/21 Wall Street in Fives - Must Read Lists for Monday 07/26/21 Wall Street in Fives - Must Read Lists at Midday 07/26/21 Fly Intel: Pre-market Movers KURA Kura Oncology $12.41 / -0.05 (-0.40%) 11/24/21 Wall Street in Fives - Must Read Lists for Wednesday 11/24/21 Wall Street in Fives - Must Read Lists at Midday 11/24/21 Fly Intel: Pre-market Movers 06/11/21 Short Report: Betting against AMC wanes while Workhorse bears spike IOVA Iovance Biotherapeutics $16.93 / +0.37 (+2.23%) 06/29/21 Wall Street in Fives - Must Read Lists for Tuesday 06/29/21 Wall Street in Fives - Must Read Lists at Midday 06/10/21 Wall Street in Fives - Must Read Lists for Thursday 06/10/21 Wall Street in Fives - Must Read Lists at Midday DCPH Deciphera $8.03 / +0.03 (+0.38%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday CVAC CureVac $40.76 / -2.91 (-6.66%) 10/12/21 Wall Street in Fives - Must Read Lists for Tuesday 10/12/21 Wall Street in Fives - Must Read Lists at Midday 10/12/21 Fly Intel: Pre-market Movers 08/16/21 Wall Street in Fives - Must Read Lists for Monday CTIC CTI BioPharma $1.68 / +0.075 (+4.69%) 12/01/21 Wall Street in Fives - Must Read Lists for Wednesday 12/01/21 Wall Street in Fives - Must Read Lists at Midday 12/01/21 Fly Intel: Pre-market Movers CGEN Compugen $4.20 / +0.03 (+0.72%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday BCYC Bicycle Therapeutics $50.35 / -2.24 (-4.26%) 10/22/21 Short Report: Virgin Galactic shorts soar to four-month highs on delayed launch 10/06/21 Before the Move: Watch Bicycle Therapeutics ahead of new cancer data BCRX BioCryst $11.18 / -0.275 (-2.40%) 11/03/21 Wall Street in Fives - Must Read Lists for Wednesday 11/03/21 Wall Street in Fives - Must Read Lists at Midday ALLO Allogene Therapeutics $17.19 / -0.45 (-2.55%) 10/08/21 Wall Street in Fives - Must Read Lists for Friday 10/08/21 Wall Street in Fives - Must Read Lists at Midday 10/08/21 Fly Intel: Pre-market Movers 10/07/21 Fly Intel: After-Hours Movers 12/08/21 San Antonio Breast Cancer Symposium: SABCS 2021 02/28/22 PDUFA Date for Pacritinib - Extended Date 12/16/21 Cellectis 12/17/21 Cellectis SPPI PTGX IOVA INBX CVAC BCYC BCRX BCAB ALLO SPPI Spectrum $1.37 / -0.005 (-0.36%) 11/03/21 Spectrum options imply 30.5% move in share price post-earnings 10/06/21 Largest borrow rate increases among liquid names PTGX Protagonist Therapeutics $32.77 / +0.43 (+1.33%) 10/11/21 Unusually active option classes on open October 11th IOVA Iovance Biotherapeutics $16.93 / +0.37 (+2.23%) 06/25/21 Iovance Biotherapeutics put volume heavy and directionally bearish 06/24/21 Iovance Biotherapeutics call volume above normal and directionally bullish 06/10/21 Iovance Biotherapeutics call volume above normal and directionally bullish INBX Inhibrx $36.50 / -0.49 (-1.32%) 09/29/21 Nineteen new option listings on September 29th CVAC CureVac $40.76 / -2.91 (-6.66%) 09/09/21 Largest borrow rate increases among liquid names 09/08/21 Largest borrow rate increases among liquid names 08/06/21 Largest borrow rate increases among liquid names 07/21/21 Largest borrow rate increases among liquid names BCYC Bicycle Therapeutics $50.35 / -2.24 (-4.26%) 07/21/21 new option listings and one option delisting on July 21st BCRX BioCryst $11.18 / -0.275 (-2.40%) 11/01/21 BioCryst put volume heavy and directionally bearish 10/11/21 BioCryst put volume heavy and directionally bearish 08/16/21 BioCryst call volume above normal and directionally bullish 08/05/21 Unusually active option classes on open August 5th BCAB BioAtla $22.46 / +0.105 (+0.47%) 06/23/21 new option listings and two option delistings on June 23rd ALLO Allogene Therapeutics $17.19 / -0.45 (-2.55%) 10/14/21 Unusually active option classes on open October 14th
Conference/Events	JMP Securities to hold a virtual summit » 10:28 12/06/21 12/06 10:28 12/06/21 10:28 ALLO Allogene Therapeutics $17.54 / -0.1 (-0.57%) , BCYC Bicycle Therapeutics $51.39 / -1.2 (-2.28%) , BCAB BioAtla $23.00 / +0.65 (+2.91%) , BCRX BioCryst $10.98 / -0.47 (-4.10%) , BPMC Blueprint Medicines $93.08 / -1.175 (-1.25%) , CLLS Cellectis $8.11 / -0.15 (-1.82%) , CGEN Compugen $4.17 / + (+0.00%) , CTIC CTI BioPharma $1.55 / -0.05 (-3.13%) , CUE Cue Biopharma $11.08 / -0.31 (-2.72%) , CVAC CureVac $42.70 / -0.97 (-2.22%) , DCPH Deciphera $8.00 / + (+0.00%) , EFTR eFfector Therapeutics $6.04 / +0.3 (+5.23%) , GMDA Gamida Cell $2.30 / -0.055 (-2.34%) , HOOK Hookipa Pharma $2.95 / +0.01 (+0.34%) , INBX Inhibrx $36.71 / -0.28 (-0.76%) , IOVA Iovance Biotherapeutics $16.75 / +0.19 (+1.15%) , KURA Kura Oncology $12.37 / -0.09 (-0.72%) , MGN Mines Management $1.13 / + (+0.00%) , MOR MorphoSys $9.19 / -0.27 (-2.85%) , NXTC NextCure $5.79 / +0.05 (+0.87%) , PTGX Protagonist Therapeutics $32.52 / +0.18 (+0.56%) , PRTA Prothena $45.07 / -1.555 (-3.34%) , SPPI Spectrum $1.37 / -0.01 (-0.73%) , SYRS Syros Pharmaceuticals $3.60 / +0.03 (+0.84%) , VOR Vor Biopharma $12.80 / +0.15 (+1.19%) Hematology & Oncology… Hematology & Oncology Virtual Summit to be held on December 6-7.Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VOR SYRS SPPI PTGX PRTA NXTC MOR KURA IOVA INBX HOOK GMDA EFTR DCPH CVAC CUE CTIC CLLS CGEN BPMC BCYC BCRX ALLO VOR Vor Biopharma $12.80 / +0.15 (+1.19%) 10/12/21 Vor Biopharma appoints Veit Schmelmer as SVP, program and alliance management 09/10/21 Vor Biopharma receives fast track designation for VOR33 from FDA 09/09/21 Vor Biopharma's VOR33 granted FDA Fast Track designation for AML 07/09/21 Vor Biopharma enters collaboration Janssen Biotech SYRS Syros Pharmaceuticals $3.60 / +0.03 (+0.84%) 10/12/21 Syros Pharmaceuticals appoints Jason Haas CFO 09/29/21 Syros reports 1st patient in dose confirmation study of ATO oral for APL 09/27/21 Syros Pharmaceuticals appointment of Conley Chee as Chief Commercial Officer 09/20/21 Syros Pharmaceuticals presents new data from Phase 1 trial of SY-5609 SPPI Spectrum $1.37 / -0.01 (-0.73%) 12/06/21 Spectrum submits new drug application for poziotinib to FDA 12/01/21 Spectrum COO Tom Riga named next president, CEO 09/19/21 Spectrum presents results from Cohort 4 of ZENITH20 clinical trial 08/06/21 Spectrum receives CRL from FDA citing deficiencies in Rolontis BLA PTGX Protagonist Therapeutics $32.52 / +0.18 (+0.56%) 12/02/21 Protagonist Therapeutics announces selection of PN-235 into Phase 2 development 11/15/21 Protagonist Therapeutics announces results from Phase 2a study of rusfertide 10/26/21 Protagonist Therapeutics earns $7.5M milestone payment from Janssen Biotech 10/11/21 Protagonist Therapeutics: FDA removes full clinical hold on rusfertide program PRTA Prothena $45.07 / -1.555 (-3.34%) 10/15/21 Prothena appoints Chris Bailey as president, Proterra Powered & Energy 10/13/21 Massachusetts electric school bus helps power electricity grid 10/01/21 Prothena names Brandon Smith as COO 07/26/21 Prothena presents new data from Alzheimer's portfolio at AAIC NXTC NextCure $5.79 / +0.05 (+0.87%) 11/14/21 NextCure provides updates on NC318, NC410 candidates at SITC Annual Meeting 10/19/21 NextCure announces three new members of its SAB 10/04/21 NextCure appoints Ellen Feigal, Anne Borgman to board of directors 07/06/21 NextCure initiates NC762 trial MOR MorphoSys $9.19 / -0.27 (-2.85%) 11/04/21 MorphoSys presents interim results from M-PLACE study with felzartamab 11/02/21 MorphoSys reports Q3 Monjuvi U.S. sales of $22M 08/26/21 MorphoSys spikes 6% after EC grants conditional MA for Minjuvi combo treatment 08/26/21 MorphoSys, Incyte get EC conditional MA for Minjuvi-lenalidomide combo for DLBCL KURA Kura Oncology $12.37 / -0.09 (-0.72%) 11/24/21 Kura Oncology's Phase 1b study of AML candidate placed on hold by FDA 10/18/21 Kura Oncology appoints Teresa Blair as Chief Legal Officer 07/29/21 Kura Oncology appoints Helen Collins to board of directors 07/06/21 Kura Oncology and Novartis announce clinical collaboration IOVA Iovance Biotherapeutics $16.75 / +0.19 (+1.15%) 11/14/21 Iovance announces data for Lifileucel in combination with Pembrolizumab 11/12/21 Iovance Biotherapeutics announces clinical data for LN-145 at SITC 2021 meeting 11/09/21 Iovance Biotherapeutics announces clinical data from TIL cell therapy 09/23/21 Iovance Biotherapeutics initiates clinical supply of TIL cell therapy INBX Inhibrx $36.71 / -0.28 (-0.76%) 12/01/21 Inhibrx granted FDA orphan-drug designation for INBRX-109 11/24/21 Inhibrx treatment of Chondrosarcoma granted FDA orphan designation 10/12/21 Inhibrx reports Phase 1 results from trial of INBRX-101 06/21/21 Inhibrx initiates potential registration-enabling Phase 2 study of INBRX-109 HOOK Hookipa Pharma $2.95 / +0.01 (+0.34%) 11/09/21 Hookipa Pharma advances HB-200 program to Phase 2 10/14/21 Hookipa Pharma announces publication on arenaviral immunotherapies in cancer 09/15/21 Hookipa announces collaboration with Merck to evaluate HB-200 with KEYTRUDA 08/12/21 Hookipa Pharma provides update on upcoming milestones GMDA Gamida Cell $2.30 / -0.055 (-2.34%) 11/15/21 Gamida Cell reports Q3 EPS ($1.18), consensus (48c) 11/11/21 Gamida Cell delays omidubicel BLA submission to FDA till 1H22 08/09/21 Tempest Therapeutics appoints Ronit Simantov to board of directors 08/02/21 Enlivex hires Tzvi Palash as Project Lead to design, construct new plant EFTR eFfector Therapeutics $6.04 / +0.3 (+5.23%) 11/24/21 eFfector Therapeutics announces publication of zotatifin preclinical data 10/07/21 eFfector Therapeutics presents positive zotatifin data in animal models of TNBC 09/09/21 eFFECTOR Therapeutics Inc trading resumes 09/09/21 eFFECTOR Therapeutics Inc trading halted, volatility trading pause DCPH Deciphera $8.00 / + (+0.00%) 11/30/21 Deciphera Pharmaceuticals trading resumes 11/30/21 Deciphera reports corporate restructuring, discontinuation of rebastinib program 11/30/21 Deciphera Pharmaceuticals trading halted, news pending 11/22/21 Deciphera gets EC approval of Qinlock for 4th line GI stromal tumor CVAC CureVac $42.70 / -0.97 (-2.22%) 11/18/21 CureVac publishes preclinical data of 2nd generation COVID candidate CV2CoV 10/15/21 CureVac holder dievini seeks registration for resale of shares 10/12/21 CureVac falls over 14% after withdrawing CVnCoV COVID vaccine candidate 10/12/21 CureVac to withdraw CVnCoV COVID-19 vaccine candidate, focus on mRNA vaccine CUE Cue Biopharma $11.08 / -0.31 (-2.72%) 11/12/21 Cue Biopharma presents updated data from CUE-101 program 09/28/21 Cue Biopharma announces publication on immunotherapeutic platforms 09/21/21 Cue Biopharma granted U.S. patents on CUE-101 08/03/21 Cue Biopharma to present corporate update at BTIG conference CTIC CTI BioPharma $1.55 / -0.05 (-3.13%) 11/30/21 CTI BioPharma announces extension of FDA review period for pacritinib NDA 10/01/21 CTI BioPharma PRE-VENT pacritinib trial does not meet primary endpoint 08/25/21 CTI BioPharma and DRI Healthcare Trust enter funding transaction for up to $135M CLLS Cellectis $8.11 / -0.15 (-1.82%) 11/18/21 Cellectis, Cytovia expand gene-edited NK cells partnership in China 11/12/21 Cellectis presents preclinical data on UCARTMESO 11/04/21 Cellectis announces release of abstracts at ASH showcase 10/19/21 Cellectis to present two presentations at the ESGCT CGEN Compugen $4.17 / + (+0.00%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial BPMC Blueprint Medicines $93.08 / -1.175 (-1.25%) 11/29/21 Blueprint Medicines to acquire Lengo Therapeutics for $250M in cash 11/09/21 Blueprint Medicines and Zai Lab announces collaboration and license agreement 07/28/21 Blueprint Medicines enters research collaboration with MD Anderson for BLU-222 06/16/21 Blueprint Medicines announces FDA approval of AYVAKIT BCYC Bicycle Therapeutics $51.39 / -1.2 (-2.28%) 11/04/21 Bicycle Therapeutics: First patient dosed in Phase I/II trial of BT7480 10/26/21 Bicycle Therapeutics, Genentech team to develop immuno-oncology therapies 10/07/21 Bicycle Therapeutics reverses higher, up 4% after volatility halt 10/07/21 Bicycle Therapeutics down 20% after data on BT5528, BT8009 trials BCRX BioCryst $10.98 / -0.47 (-4.10%) 12/03/21 BioCryst reports inducement grants under Nasdaq listing rule 12/02/21 Praxis Precision Medicines appoints Megan Sniecinski as CBO 11/29/21 BioCryst begins patient enrollment in REDEEM-2 trial of BCX9930 11/24/21 BioCryst CFO buys 35K shares of common stock ALLO Allogene Therapeutics $17.54 / -0.1 (-0.57%) 12/01/21 Allogene announces call to review ALPHA, ALPHA2, UNIVERSAL data 11/04/21 Allogene Therapeutics to showcase clinical data at ASH annual meeting 10/07/21 Allogene Therapeutics trading resumes 10/07/21 Allogene says FDA put clinical hold on AlloCar T clinical trials ALLO BCYC BCAB BCRX BPMC CLLS CGEN CTIC CUE CVAC DCPH EFTR GMDA HOOK INBX IOVA KURA MGN MOR NXTC PTGX PRTA SPPI SYRS VOR ALLO Allogene Therapeutics $17.54 / -0.1 (-0.57%) 12/03/21 Canaccord Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord 10/19/21 Cowen Allogene Therapeutics assumed with an Outperform at Cowen 10/12/21 JMP Securities Allogene Therapeutics price target lowered to $27 from $53 at JMP Securities 10/08/21 Fly Intel: Top five analyst downgrades BCYC Bicycle Therapeutics $51.39 / -1.2 (-2.28%) 10/14/21 JMP Securities Bicycle Therapeutics price target raised to $85 from $53 at JMP Securities 10/11/21 Canaccord Bicycle Therapeutics price target raised to $60 from $40 at Canaccord 10/08/21 Oppenheimer Bicycle Therapeutics price target raised to $65 from $47 at Oppenheimer 10/08/21 B. Riley Bicycle Therapeutics price target raised to $72 from $56 at B. Riley BCAB BioAtla $23.00 / +0.65 (+2.91%) 10/14/21 BTIG BioAtla assumed with a Buy at BTIG 06/28/21 Roth Capital BioAtla initiated with a Buy at Roth Capital 05/04/21 Credit Suisse BioAtla assumed with an Outperform at Credit Suisse 05/04/21 JPMorgan BioAtla price target raised to $64 from $45 at JPMorgan BCRX BioCryst $10.98 / -0.47 (-4.10%) 11/22/21 Piper Sandler BioCryst financing lifts one of two overhangs, says Piper Sandler 11/04/21 Barclays BioCryst price target lowered to $17 from $21 at Barclays 11/03/21 Piper Sandler BioCryst earnings pullback a buying opportunity, says Piper Sandler 08/06/21 Jefferies BioCryst downgraded to Hold from Buy at Jefferies BPMC Blueprint Medicines $93.08 / -1.175 (-1.25%) 12/01/21 Raymond James Blueprint Medicines added to Analyst Current Favorites list at Raymond James 11/29/21 Stifel Stifel expects neutral reaction for Blueprint acquisition of Lengo Therapeutics 11/29/21 Piper Sandler Blueprint acquisition may surprise investors looking for buyout, says Piper 11/19/21 Morgan Stanley Blueprint Medicines assumed with an Equal Weight at Morgan Stanley CLLS Cellectis $8.11 / -0.15 (-1.82%) 11/30/21 JMP Securities Cellectis initiated with an Outperform at JMP Securities 11/08/21 William Blair Cellectis downgraded to Market Perform at William Blair on slow execution 11/08/21 William Blair Cellectis downgraded to Market Perform from Outperform at William Blair 10/08/21 Baird Baird cuts Cellectis to Neutral after partner Allogene's clinical hold CGEN Compugen $4.17 / + (+0.00%) CTIC CTI BioPharma $1.55 / -0.05 (-3.13%) 12/01/21 Lake Street CTI BioPharma delay creates buying opportunity, says Lake Street 10/04/21 Lake Street CTI BioPharma should be bought on weakness after PRE-VENT miss, says Lake Street 08/09/21 BTIG CTI BioPharma initiated with a Buy at BTIG 06/01/21 Lake Street CTI BioPharma price target raised to $15 from $13 at Lake Street CUE Cue Biopharma $11.08 / -0.31 (-2.72%) CVAC CureVac $42.70 / -0.97 (-2.22%) 10/22/21 Fly Intel: Top five analyst initiations 10/22/21 Deutsche Bank CureVac initiated with a Hold at Deutsche Bank 07/01/21 Berenberg CureVac COVID vaccine data may be enough for EU approval, says Berenberg 06/30/21 CureVac announces COVID vaccine candidate demonstrates 48% efficacy DCPH Deciphera $8.00 / + (+0.00%) 12/01/21 H.C. Wainwright Deciphera price target lowered to $15 from $25 at H.C. Wainwright 11/30/21 Piper Sandler Deciphera price target lowered to $11 from $14 at Piper Sandler 11/08/21 Barclays Deciphera downgraded to Equal Weight at Barclays after GIST trial miss 11/08/21 Canaccord Deciphera downgraded to Hold at Canaccord EFTR eFfector Therapeutics $6.04 / +0.3 (+5.23%) 11/08/21 Stifel eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism 11/08/21 Stifel eFfector Therapeutics upgraded to Buy from Hold at Stifel 10/12/21 Credit Suisse eFfector Therapeutics initiated with an Outperform at Credit Suisse 10/04/21 Mizuho eFfector Therapeutics initiated with a Buy at Mizuho GMDA Gamida Cell $2.30 / -0.055 (-2.34%) 11/16/21 H.C. Wainwright Gamida Cell price target lowered to $22 from $27 at H.C. Wainwright 11/16/21 Oppenheimer Gamida Cell price target lowered to $15 from $17 at Oppenheimer 11/15/21 Piper Sandler Gamida Cell price target lowered to $13 from $23 at Piper Sandler 11/01/21 Alliance Global Partners Gamida Cell initiated with a Buy at Alliance Global Partners HOOK Hookipa Pharma $2.95 / +0.01 (+0.34%) 11/12/21 Morgan Stanley Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update 11/12/21 Morgan Stanley Hookipa Pharma downgraded to Equal Weight from Overweight at Morgan Stanley 11/11/21 H.C. Wainwright Hookipa Pharma price target lowered to $15 from $21 at H.C. Wainwright 11/10/21 JMP Securities Hookipa Pharma price target lowered to $11 from $25 at JMP Securities INBX Inhibrx $36.71 / -0.28 (-0.76%) 11/10/21 Credit Suisse Inhibrx price target raised to $53 from $44 at Credit Suisse 11/02/21 JMP Securities Inhibrx price target raised to $53 from $46 at JMP Securities 09/21/21 JMP Securities Inhibrx initiated with an Outperform at JMP Securities 04/26/21 Credit Suisse Inhibrx assumed with an Outperform at Credit Suisse IOVA Iovance Biotherapeutics $16.75 / +0.19 (+1.15%) 11/15/21 Oppenheimer Iovance price target lowered to $31 from $38 at Oppenheimer 11/05/21 H.C. Wainwright Iovance Biotherapeutics price target lowered to $43 from $46 at H.C. Wainwright 11/05/21 Piper Sandler Iovance Biotherapeutics price target raised to $20 from $18 at Piper Sandler 06/29/21 Chardan Iovance data show activity but 'not a home run,' says Chardan KURA Kura Oncology $12.37 / -0.09 (-0.72%) 11/26/21 Credit Suisse Kura Oncology price target lowered to $21 from $40 at Credit Suisse 11/24/21 H.C. Wainwright Kura Oncology price target lowered to $32 from $43 at H.C. Wainwright 05/04/21 Credit Suisse Kura Oncology assumed with an Outperform at Credit Suisse 04/26/21 Credit Suisse Kura Oncology assumed with an Outperform at Credit Suisse MGN Mines Management $1.13 / + (+0.00%) MOR MorphoSys $9.19 / -0.27 (-2.85%) 11/12/21 Morgan Stanley MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley 09/27/21 Citi MorphoSys downgraded to Neutral from Buy at Citi 09/13/21 Goldman Sachs MorphoSys reinstated with a Neutral at Goldman Sachs 09/02/21 Barclays MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays NXTC NextCure $5.79 / +0.05 (+0.87%) 11/05/21 Piper Sandler NextCure's Phase II NC318 study continuing weekly dosing, says Piper Sandler 08/08/21 Piper Sandler NextCure price target lowered to $21 from $26 at Piper Sandler 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist PTGX Protagonist Therapeutics $32.52 / +0.18 (+0.56%) 11/15/21 JMP Securities Protagonist Therapeutics price target raised to $70 from $60 at JMP Securities 11/04/21 Piper Sandler Piper 'pleasantly surprised' by Protagonist Therapeutics' ASH abstracts 10/13/21 JMP Securities Protagonist Therapeutics price target raised to $60 from $47 at JMP Securities 10/12/21 JPMorgan JPMorgan upgrades Protagonist after 'rapid' clinical hold removal PRTA Prothena $45.07 / -1.555 (-3.34%) 11/19/21 JMP Securities Prothena initiated with an Outperform at JMP Securities 09/30/21 RBC Capital Prothena price target raised to $82 from $59 at RBC Capital 09/27/21 Oppenheimer Prothena price target raised to $100 from $90 at Oppenheimer 09/20/21 Fox Advisors Prothena initiated with an Overweight at Fox Advisors SPPI Spectrum $1.37 / -0.01 (-0.73%) 08/18/21 B. Riley Spectrum price target lowered to $6 from $8 at B. Riley 06/01/21 H.C. Wainwright H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility SYRS Syros Pharmaceuticals $3.60 / +0.03 (+0.84%) 09/27/21 Roth Capital Veteran Chee coming aboard a positive for Syros, says Roth Capital 09/23/21 Roth Capital Syros Pharmaceuticals price target raised to $23 from $20 at Roth Capital 05/06/21 Piper Sandler Syros Pharmaceuticals selloff a buying opportunity, says Piper Sandler 03/05/21 Alliance Global Partners Syros price target lowered to $14 from $18 at Alliance Global Partners VOR Vor Biopharma $12.80 / +0.15 (+1.19%) 12/03/21 Baird Baird start Vor Biopharma with an Outperform ahead of AML data 12/02/21 Baird Vor Biopharma initiated with an Outperform at Baird 12/01/21 Oppenheimer Vor Biopharma initiated with an Outperform at Oppenheimer 10/19/21 JMP Securities Vor Biopharma initiated with an Outperform at JMP Securities VOR SYRS SPPI PTGX PRTA NXTC MOR KURA IOVA INBX HOOK GMDA EFTR DCPH CVAC CUE CTIC CLLS CGEN BPMC BCYC BCRX BCAB ALLO VOR Vor Biopharma $12.80 / +0.15 (+1.19%) 11/10/21 Vor Biopharma reports Q3 EPS (50c), consensus (62c) 08/09/21 Vor Biopharma reports Q2 EPS (50c), consensus (50c) SYRS Syros Pharmaceuticals $3.60 / +0.03 (+0.84%) 11/05/21 Syros Pharmaceuticals reports Q3 EPS (41c), consensus (44c) 08/05/21 Syros Pharmaceuticals reports Q2 EPS (36c), consensus (37c) SPPI Spectrum $1.37 / -0.01 (-0.73%) 11/10/21 Spectrum reports Q3 adjusted EPS (16c), consensus (28c) 08/12/21 Spectrum reports Q2 EPS (25c), consensus (25c) PTGX Protagonist Therapeutics $32.52 / +0.18 (+0.56%) 11/03/21 Protagonist Therapeutics reports Q3 EPS (70c), consensus (67c) 08/04/21 Protagonist Therapeutics reports Q2 EPS (69c), consensus (51c) PRTA Prothena $45.07 / -1.555 (-3.34%) 11/04/21 Prothena reports Q3 EPS $2.13, consensus $2.28 08/05/21 Prothena reports Q2 EPS 58c, consensus 55c NXTC NextCure $5.79 / +0.05 (+0.87%) 11/04/21 NextCure reports Q3 EPS (65c), consensus (67c) 08/05/21 NextCure reports Q2 EPS (65c), consensus (61c) MOR MorphoSys $9.19 / -0.27 (-2.85%) 07/26/21 MorphoSys narrows FY21 revenue view to EUR 155M-EUR180M from EUR 150M-EUR 200M KURA Kura Oncology $12.37 / -0.09 (-0.72%) 11/04/21 Kura Oncology reports Q3 EPS (50c), consensus (54C) 08/05/21 Kura Oncology reports Q2 EPS (51c), consensus (49c) IOVA Iovance Biotherapeutics $16.75 / +0.19 (+1.15%) 11/04/21 Iovance Biotherapeutics reports Q3 EPS (53c), consensus (53c) INBX Inhibrx $36.71 / -0.28 (-0.76%) 11/09/21 Inhibrx reports Q3 EPS (54c), consensus (57c) 08/09/21 Inhibrx reports Q2 EPS (55c), consensus (56c) HOOK Hookipa Pharma $2.95 / +0.01 (+0.34%) 11/10/21 Hookipa Pharma reports Q3 EPS (61c), consensus (52c) 08/12/21 Hookipa Pharma reports Q2 EPS (52c), consensus (53c) GMDA Gamida Cell $2.30 / -0.055 (-2.34%) 08/11/21 Gamida Cell reports Q2 EPS (76c), consensus (40c) EFTR eFfector Therapeutics $6.04 / +0.3 (+5.23%) 11/08/21 eFfector Therapeutics reports Q3 EPS 42c, consensus (25c) DCPH Deciphera $8.00 / + (+0.00%) 11/02/21 Deciphera Pharmaceuticals reports Q3 EPS ($1.37), consensus ($1.28) 08/03/21 Deciphera reports Q2 EPS ($1.21), consensus ($1.15) CVAC CureVac $42.70 / -0.97 (-2.22%) 08/16/21 CureVac reports Q2 revenue EUR 22.4M vs. EUR 34.5M a year ago CUE Cue Biopharma $11.08 / -0.31 (-2.72%) 08/17/21 Cue Biopharma reports Q2 EPS (33c), consensus (42c) CTIC CTI BioPharma $1.55 / -0.05 (-3.13%) 08/05/21 CTI BioPharma reports Q2 EPS (21c), consensus (21c) CLLS Cellectis $8.11 / -0.15 (-1.82%) 11/04/21 Cellectis reports Q3 EPS (82c) consensus (83c) 08/05/21 Cellectis reports Q2 EPS (80c), consensus (73c) CGEN Compugen $4.17 / + (+0.00%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) BPMC Blueprint Medicines $93.08 / -1.175 (-1.25%) 10/28/21 Blueprint Medicines sees 2021 revenue $170M-$180M, consensus $148.37M 10/28/21 Blueprint Medicines reports Q3 EPS ($2.00), consensus ($1.63) 07/29/21 Blueprint Medicines reports Q2 EPS ($1.86), consensus ($1.86) BCYC Bicycle Therapeutics $51.39 / -1.2 (-2.28%) 11/04/21 Bicycle Therapeutics reports Q3 EPS (59c), consensus (61c) 08/05/21 Bicycle Therapeutics reports Q2 EPS (74c), consensus (71c) BCRX BioCryst $10.98 / -0.47 (-4.10%) 11/03/21 BioCryst sees current cash runway funding operations into 2023 11/03/21 BioCryst sees FY21 ORLADEYO revenue to $115M-$120M 11/03/21 BioCryst reports Q3 EPS (33c), consensus (29c) 08/05/21 BioCryst reports Q2 EPS (24c), consensus (24c) BCAB BioAtla $23.00 / +0.65 (+2.91%) 08/13/21 BioAtla reports Q2 collaboration revenue $250,000 vs $190,000 last year ALLO Allogene Therapeutics $17.54 / -0.1 (-0.57%) 11/04/21 Allogene Therapeutics reports Q3 EPS (57c), consensus (56c) 08/04/21 Allogene Therapeutics reports Q2 EPS (53c), consensus (55c) 13 Oct 11 Aug 16 Jun 01 Apr 24 Mar 05 Feb 28 Jan 20 Jan 16 Dec 16 Dec 11 Dec 09 Dec 09 Dec SPPI CVAC CGEN SPPI Spectrum $1.37 / -0.01 (-0.73%) 12/02/21 Spectrum could be 'undervalued' if poziotinib hits in NSCLC, Dealreporter says CVAC CureVac $42.70 / -0.97 (-2.22%) 11/29/21 Judge halts Biden's health worker vaccine mandate in 10 states, The Hill says 07/01/21 CureVac plans to continue work on Covid-19 vaccine, CEO tells CNBC 06/08/21 E.U. health ministers meeting suggests CureVac COVID vaccine delayed, BI says CGEN Compugen $4.17 / + (+0.00%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says SPPI PTGX PRTA MOR KURA IOVA DCPH CVAC CTIC CGEN BCYC BCRX ALLO SPPI Spectrum $1.37 / -0.01 (-0.73%) 08/06/21 Wall Street in Fives - Must Read Lists for Friday 08/06/21 Wall Street in Fives - Must Read Lists at Midday 08/06/21 Fly Intel: Pre-market Movers PTGX Protagonist Therapeutics $32.52 / +0.18 (+0.56%) 10/11/21 Wall Street in Fives - Must Read Lists for Monday 09/17/21 Wall Street in Fives - Must Read Lists for Friday 09/17/21 Wall Street in Fives - Must Read Lists at Midday 09/17/21 Fly Intel: Pre-market Movers PRTA Prothena $45.07 / -1.555 (-3.34%) 07/12/21 Wall Street in Fives - Must Read Lists for Monday 07/12/21 Wall Street in Fives - Must Read Lists at Midday 06/07/21 Biotech shares rise as FDA approves Biogen's controversial Alzheimer's drug MOR MorphoSys $9.19 / -0.27 (-2.85%) 08/26/21 Fly Intel: After-Hours Movers 07/26/21 Wall Street in Fives - Must Read Lists for Monday 07/26/21 Wall Street in Fives - Must Read Lists at Midday 07/26/21 Fly Intel: Pre-market Movers KURA Kura Oncology $12.37 / -0.09 (-0.72%) 11/24/21 Wall Street in Fives - Must Read Lists for Wednesday 11/24/21 Wall Street in Fives - Must Read Lists at Midday 11/24/21 Fly Intel: Pre-market Movers 06/11/21 Short Report: Betting against AMC wanes while Workhorse bears spike IOVA Iovance Biotherapeutics $16.75 / +0.19 (+1.15%) 06/29/21 Wall Street in Fives - Must Read Lists for Tuesday 06/29/21 Wall Street in Fives - Must Read Lists at Midday 06/10/21 Wall Street in Fives - Must Read Lists for Thursday 06/10/21 Wall Street in Fives - Must Read Lists at Midday DCPH Deciphera $8.00 / + (+0.00%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday CVAC CureVac $42.70 / -0.97 (-2.22%) 10/12/21 Wall Street in Fives - Must Read Lists for Tuesday 10/12/21 Wall Street in Fives - Must Read Lists at Midday 10/12/21 Fly Intel: Pre-market Movers 08/16/21 Wall Street in Fives - Must Read Lists for Monday CTIC CTI BioPharma $1.55 / -0.05 (-3.13%) 12/01/21 Wall Street in Fives - Must Read Lists for Wednesday 12/01/21 Wall Street in Fives - Must Read Lists at Midday 12/01/21 Fly Intel: Pre-market Movers CGEN Compugen $4.17 / + (+0.00%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday BCYC Bicycle Therapeutics $51.39 / -1.2 (-2.28%) 10/22/21 Short Report: Virgin Galactic shorts soar to four-month highs on delayed launch 10/06/21 Before the Move: Watch Bicycle Therapeutics ahead of new cancer data BCRX BioCryst $10.98 / -0.47 (-4.10%) 11/03/21 Wall Street in Fives - Must Read Lists for Wednesday 11/03/21 Wall Street in Fives - Must Read Lists at Midday ALLO Allogene Therapeutics $17.54 / -0.1 (-0.57%) 10/08/21 Wall Street in Fives - Must Read Lists for Friday 10/08/21 Wall Street in Fives - Must Read Lists at Midday 10/08/21 Fly Intel: Pre-market Movers 10/07/21 Fly Intel: After-Hours Movers 12/08/21 San Antonio Breast Cancer Symposium: SABCS 2021 02/28/22 PDUFA Date for Pacritinib - Extended Date 12/16/21 Cellectis 12/17/21 Cellectis SPPI PTGX IOVA INBX CVAC BCYC BCRX BCAB ALLO SPPI Spectrum $1.37 / -0.01 (-0.73%) 11/03/21 Spectrum options imply 30.5% move in share price post-earnings 10/06/21 Largest borrow rate increases among liquid names PTGX Protagonist Therapeutics $32.52 / +0.18 (+0.56%) 10/11/21 Unusually active option classes on open October 11th IOVA Iovance Biotherapeutics $16.75 / +0.19 (+1.15%) 06/25/21 Iovance Biotherapeutics put volume heavy and directionally bearish 06/24/21 Iovance Biotherapeutics call volume above normal and directionally bullish 06/10/21 Iovance Biotherapeutics call volume above normal and directionally bullish INBX Inhibrx $36.71 / -0.28 (-0.76%) 09/29/21 Nineteen new option listings on September 29th CVAC CureVac $42.70 / -0.97 (-2.22%) 09/09/21 Largest borrow rate increases among liquid names 09/08/21 Largest borrow rate increases among liquid names 08/06/21 Largest borrow rate increases among liquid names 07/21/21 Largest borrow rate increases among liquid names BCYC Bicycle Therapeutics $51.39 / -1.2 (-2.28%) 07/21/21 new option listings and one option delisting on July 21st BCRX BioCryst $10.98 / -0.47 (-4.10%) 11/01/21 BioCryst put volume heavy and directionally bearish 10/11/21 BioCryst put volume heavy and directionally bearish 08/16/21 BioCryst call volume above normal and directionally bullish 08/05/21 Unusually active option classes on open August 5th BCAB BioAtla $23.00 / +0.65 (+2.91%) 06/23/21 new option listings and two option delistings on June 23rd ALLO Allogene Therapeutics $17.54 / -0.1 (-0.57%) 10/14/21 Unusually active option classes on open October 14th
Conference/Events	Compugen participates in a conference call with JMP Securities » 04:55 11/29/21 11/29 04:55 11/29/21 04:55 CGEN Compugen $4.54 / -0.08 (-1.73%) Conference call with… Conference call with management will be held on November 29 hosted by JMP Securities. ShowHide Related Items >><< Company News Earnings Periodicals On The Fly Events CGEN Compugen $4.54 / -0.08 (-1.73%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial CGEN Compugen $4.54 / -0.08 (-1.73%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) CGEN Compugen $4.54 / -0.08 (-1.73%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says CGEN Compugen $4.54 / -0.08 (-1.73%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday 11/29/21 Compugen - CGEN

Conference/Events	Compugen participates in a conference call with JMP Securities » 13:02 11/22/21 11/22 13:02 11/22/21 13:02 CGEN Compugen $4.54 / -0.18 (-3.81%) Conference call with… Conference call with management will be held on November 29 hosted by JMP Securities. ShowHide Related Items >><< Company News Earnings Periodicals On The Fly Events CGEN Compugen $4.54 / -0.18 (-3.81%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial CGEN Compugen $4.54 / -0.18 (-3.81%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) CGEN Compugen $4.54 / -0.18 (-3.81%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says CGEN Compugen $4.54 / -0.18 (-3.81%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday 11/29/21 Compugen - CGEN
Conference/Events	Society for Immunotherapy of Cancer to hold annual meeting » 04:55 11/14/21 11/14 04:55 11/14/21 04:55 CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) , REGN Regeneron $631.22 / +4.71 (+0.75%) , ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) , ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) , ALXO ALX Oncology $45.94 / +2.07 (+4.72%) , ARAV Aravive $4.03 / +0.24 (+6.33%) , CGEN Compugen $5.87 / -1.29 (-18.02%) , CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) , FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) , GILD Gilead $67.48 / +0.07 (+0.10%) , GRCL Gracell $10.87 / -0.36 (-3.21%) , HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) , IMAB I-Mab $60.16 / -0.85 (-1.39%) , IMMP Immutep $4.27 / +0.27 (+6.75%) , IMV IMV Inc. $1.55 / +0.01 (+0.65%) , IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) , LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) , MRK Merck $84.02 / + (+0.00%) , MRNA Moderna $231.26 / +5.3 (+2.35%) , SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) , SGEN Seagen $178.94 / +1.395 (+0.79%) , PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) , ONCS OncoSec $1.75 / +0.03 (+1.74%) , ONCR Oncorus $6.01 / -5.195 (-46.38%) , NXTC NextCure $6.42 / -0.18 (-2.73%) , NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) , NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) , STTK Shattuck Labs $12.52 / -0.63 (-4.79%) , TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) , ANCR Ancor Communications / + SITC 2021 to be held in… SITC 2021 to be held in Washington, D.C. on November 10-14. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TPST STTK SNSE SGEN REGN PSTX ONCS ONCR NXTC NRIX NLTX MRNA MRK LIFE IOVA IMV IMMP IMAB HARP GRCL GILD FATE CRVS CRSP CGEN ARAV ALXO ALEX ACHL TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 11/12/21 Tempest Therapeutics presents data supporting dual mechanism of TPST-1495 11/08/21 Tempest Therapeutics announces issuance of patents for TPST-1495 09/20/21 Tempest Therapeutics doses first patient in randomized study of TPST-1120 09/13/21 Tempest Therapeutics enters into exclusive license agreement STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 11/09/21 Shattuck Labs announces preliminary clinical data from ongoing ARC trials 08/18/21 Codiak appoints Lini Pandite to board of directors 06/01/21 Shattuck Labs appoints Abhinav Shukla as CTO 05/17/21 Ecor1 Capital reports 7.9% passive stake in Shattuck Labs SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 11/12/21 Sensei Biotherapeutics presents preclinical data for SNS-101 11/09/21 Sensei Biotherapeutics expects cash to fund operations into 1H24 08/04/21 Sensei Biotherapeutics expects cash to fund operations into 1H of 2024 08/02/21 Sensei Biotherapeutics appoints Kristian Humer to its board of directors SGEN Seagen $178.94 / +1.395 (+0.79%) 10/28/21 Seagen reports Q3 Adcetris revenue $184.8M, Padcev revenue $95M 10/28/21 Seagen now sees FY Adcetris net product sales $700M-$710M 10/12/21 Seagen, Astellas Pharma complete patient enrollment for Cohort K of EV-103 trial 09/28/21 Seagen completes patient enrollment in MOUNTAINEER trial REGN Regeneron $631.22 / +4.71 (+0.75%) 11/12/21 Regeneron announces $3B share repurchase program 11/12/21 Roche announces Ronapreve approved by EC to treat, prevent COVID-19 11/12/21 Regeneron reports EC approves antibody cocktail to treat, prevent COVID-19 11/11/21 Regeneron: CHMP recommends EU approval of antibody cocktail to treat Covid PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) 10/13/21 Poseida Therapeutics announces new leadership appointments 10/12/21 Poseida Therapeutics enters research collaboration with Takeda Pharmaceutical 08/31/21 Poseida reports preliminary results from Phase 1 trial of P-PSMA-101 08/30/21 Poseida Therapeutics: FDA clears IND application for P-BCMA-ALLO1 ONCS OncoSec $1.75 / +0.03 (+1.74%) 10/20/21 OncoSec Chief Scientific Officer Chris Twitty, Ph.D., to step down 08/16/21 OncoSec establishes Leadership Committee, interim CEO stepping down 07/06/21 OncoSec announces agreement with Merck ONCR Oncorus $6.01 / -5.195 (-46.38%) 11/12/21 Oncorus sinks after data but Piper 'aggressive buyers on the open' 11/12/21 Oncorus report initial data from ongoing Phase 1 trial of ONCR-177 at SITC 2021 11/11/21 Oncorus announces exclusive licensing agreement with Gaeta Therapeutics 08/04/21 Oncorus sees cash, cash equivalents sufficient to fund operations into late 2023 NXTC NextCure $6.42 / -0.18 (-2.73%) 10/19/21 NextCure announces three new members of its SAB 10/04/21 NextCure appoints Ellen Feigal, Anne Borgman to board of directors 07/06/21 NextCure initiates NC762 trial 06/21/21 NextCure announces publication of NC410 preclinical data NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) 11/12/21 Nurix Therapeutics presents data from preclinical studies on NX-0255 11/12/21 Nurix Therapeutics announces IND clearance for DeTIL-0255 10/27/21 Nurix Therapeutics announces initial data from Phase 1a trial of NX-2127 09/30/21 Nurix Therapeutics expands board of directors with two additional appointments NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) 11/12/21 Neoleukin Therapeutics presents NL-201 preclinical data at SITC 2021 11/04/21 Neoleukin Therapeutics sees sufficient cash to fund operations into 2H23 09/29/21 Neoleukin Therapeutics to present data on NL-CVX1 at IDWeek 2021 09/09/21 Neoleukin Therapeutics appoints Bill Arthur as VP, head of research MRNA Moderna $231.26 / +5.3 (+2.35%) 11/12/21 Moderna reports interim data from Phase 1 clinical study of mRNA-2752 11/11/21 Moderna disagrees NIAID scientists co-invented mRNA sequence claims 11/10/21 Germany recommends Pfizer vaccine over Moderna for young, pregnant 11/09/21 Moderna files to expand CMA for COVID-19 vaccine to include children MRK Merck $84.02 / + (+0.00%) 11/11/21 Trevena appoints Patricia Drake as CCO, Yoder as CBO 11/11/21 Merck initiates Phase 3 study evaluating VERQUVO 11/10/21 Merck to supply 1.6M courses of molnupiravir to Japan for $1.2B upon approval 11/09/21 Merck, Ridgeback: U.S. to purchase 1.4M additional courses of molnupiravir LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 11/09/21 aTyr Pharma presents research on effects of ATYR2810 11/02/21 BriaCell appoints Gross to board, separately enters 6-month marketing contract 10/06/21 aTyr Pharma appoints Robert Ashworth as VP, regulatory affairs 09/13/21 aTyr Pharma announces positive data from Phase 1b/2a trial for ATYR1923 IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 11/12/21 Iovance Biotherapeutics announces clinical data for LN-145 at SITC 2021 meeting 11/09/21 Iovance Biotherapeutics announces clinical data from TIL cell therapy 09/23/21 Iovance Biotherapeutics initiates clinical supply of TIL cell therapy 06/29/21 Iovance Biotherapeutics reports clinical data for TIL therapy LN-145 IMV IMV Inc. $1.55 / +0.01 (+0.65%) 10/07/21 Immunotherapeutic capacity of IMV's DPX delivery platform featured at AACR 08/10/21 IMV Inc. announces final topline results from DeCidE1 08/04/21 IMV Inc. CEO Frederic Ors departs, Andrew Hall appointed interim CEO 06/11/21 Shareholder raises concerns over IMV Inc.'s outlook IMMP Immutep $4.27 / +0.27 (+6.75%) 11/09/21 Immutep reports data from final Phase IIb AIPAC study 11/02/21 Immutep granted Chinese patent for eftilagimod alpha 10/29/21 Immutep receives EMA scientific advice for further clinical development of efti 10/28/21 Immutep estimates cash reach into December 2023 IMAB I-Mab $60.16 / -0.85 (-1.39%) 11/10/21 Jumpcan to pay I-Mab RMB 224M upfront in eftansomatropin alfa partnership 11/08/21 I-Mab announces strategic collaboration with Roche Diagnostics 11/01/21 I-Mab appoints new CFO and new Chief Strategy Officer 10/26/21 I-Mab announces partnership with Sinopharm HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) 11/12/21 Harpoon Therapeutics presents data on TriTAC-XR T cell engager platform 10/26/21 Harpoon Therapeutics CEO Jerry McMahon to retire, Julie Eastland to succeed 09/23/21 Harpoon Therapeutics CFO buys 10.3K shares of common stock 06/04/21 Harpoon Therapeutics presents updated data for phase 1/2a trial for HPN424 GRCL Gracell $10.87 / -0.36 (-3.21%) 08/16/21 Gracell signs license agreement with FutureGen Biopharm 06/02/21 Gracell reschedules clinical update conference call 05/28/21 Gracell Biotechnologies Inc (ADS) trading resumes 05/28/21 Gracell Biotechnologies Inc (ADS) trading halted, volatility trading pause GILD Gilead $67.48 / +0.07 (+0.10%) 11/10/21 Gilead says Phase 2B Trodelvy study meets primary ORR endpoint 10/29/21 Gilead announces interim results from BICSTaR study 10/28/21 Gilead announces Trodelvy-Keytruda trial collaboration with Merck 10/26/21 Gilead and Merck to begin Phase 2 clinical study of islatravir and lenacapavir FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 11/09/21 Fate Therapeutics announces abstract highlighting FT538, FT573 11/04/21 Fate Therapeutics announces presentations at ASH annual meeting 10/01/21 Fate Therapeutics announces presentation at SITC annual meeting 09/15/21 Fate Therapeutics announces publication of FT538 preclinical data CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 11/12/21 Corvus Pharmaceuticals presents updated data from mupadolimab Phase 1/1b trial 10/27/21 Corvus' China partner Angel approved by China regulator to begin TCL study 10/25/21 Corvus Pharmaceuticals-licensed CPI-818 approved for clinical trials in China 09/22/21 Corvus Pharmaceuticals provides update on mupadolimab in viruses and tumors CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 10/14/21 Crispr Therapeutics appoints Brendan Smith as Chief Financial Officer 10/14/21 ARK Investment bought 678K shares of Crispr Therapeutics on Wednesday 10/12/21 Crispr announces updated results in trial of CTX110 for large B-cell lymphomas 10/12/21 Cathie Wood's ARK Investment bought 248K shares of Crispr Therapeutics on Monday CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial ARAV Aravive $4.03 / +0.24 (+6.33%) 11/12/21 Aravive announces preliminary data from Phase 1b of ABV-500 with cabozantinib 11/09/21 Aravive announces preliminary data from Phase 1b trial evaluating ABV-500 08/09/21 Aravive announces first patient dosed in Phase 1b/2 clinical trial of AVB-500 08/05/21 Aravive expects cash, cash equivalents to fund operations into H2 of 2022 ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 11/09/21 ALX Oncology announces updated data from ongoing ASPEN-01 clinical trial 11/04/21 ALX Oncology to present early clinical data from ASPEN-02 10/21/21 ALX Oncology doses first patient in ASPEN-05 study of evorpacept 10/07/21 ALX Oncology announces acquisition of ScalmiBio ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) 11/12/21 Alexander & Baldwin sells Kukui'ula residential development 07/27/21 Alexander & Baldwin raises quarterly dividend to 18c from 16c per share ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 11/12/21 Achilles Therapeutics presents data on cNeT from VELOS Process 2 manufacturing 11/09/21 Achilles Therapeutics expects cash to fund operations into 2H of 2023 10/22/21 Achilles Therapeutics presents data at ESGCT on company's MAP 10/12/21 Achilles Therapeutics joins the NA-ATTC consortium CRSP REGN ACHL ALEX ALXO ARAV CGEN CRVS FATE GILD GRCL HARP IMAB IMMP IMV IOVA LIFE MRK MRNA SNSE SGEN PSTX ONCS ONCR NXTC NRIX NLTX STTK TPST ANCR CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 11/08/21 Goldman Sachs Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs 11/04/21 Raymond James ASH abstracts justify Crispr Therapeutics concerns, says Raymond James 11/04/21 Oppenheimer Crispr Therapeutics price target lowered to $172 from $185 at Oppenheimer 10/19/21 SVB Leerink Crispr Therapeutics initiated with an Outperform at SVB Leerink REGN Regeneron $631.22 / +4.71 (+0.75%) 11/10/21 Cantor Fitzgerald Regeneron price target raised to $760 from $700 at Cantor Fitzgerald 11/09/21 Benchmark Benchmark sees signs Regeneron may be planning large acquisition 11/05/21 Fly Intel: Top five analyst downgrades 11/05/21 Benchmark Regeneron downgraded to Hold from Buy at Benchmark ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 11/12/21 Piper Sandler Achilles provides clinical update for ATL001 trials, says Piper Sandler 08/10/21 Piper Sandler Achilles Therapeutics price target lowered to $23 from $25 at Piper Sandler 06/29/21 Chardan Iovance data show activity but 'not a home run,' says Chardan 05/19/21 Chardan Iovance Biotherapeutics price target lowered to $51 from $54 at Chardan ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) 07/30/21 Piper Sandler Alexander & Baldwin upgraded to Overweight from Neutral at Piper Sandler 12/23/20 Piper Sandler Alexander & Baldwin price target raised to $17 from $13 at Piper Sandler ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 11/09/21 Piper Sandler ALX Oncology price target lowered to $85 from $97 at Piper Sandler 11/09/21 H.C. Wainwright H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity 11/04/21 Piper Sandler ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler 09/29/21 Stifel ALX Oncology initiated with a Buy at Stifel ARAV Aravive $4.03 / +0.24 (+6.33%) 11/09/21 Piper Sandler Aravive data show preliminary efficacy in ccRCC, says Piper Sandler 08/06/21 Piper Sandler Aravive price target lowered to $18 from $20 at Piper Sandler 04/27/21 Piper Sandler Aravive doses first patient in Phase III AVB-500 trial, says Piper Sandler 03/08/21 Fly Intel: Top five analyst initiations CGEN Compugen $5.87 / -1.29 (-18.02%) CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 09/22/21 Roth Capital Corvus recent rally due to AstraZeneca data, says Roth Capital 08/03/21 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald 08/03/21 Mizuho Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho 07/16/21 H.C. Wainwright Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 11/08/21 Citi Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations 11/08/21 Citi Fate Therapeutics upgraded to Buy from Neutral at Citi 11/05/21 Roth Capital Fate Therapeutics price target lowered to $60 from $90 at Roth Capital 08/26/21 Fly Intel: Top five analyst initiations GILD Gilead $67.48 / +0.07 (+0.10%) 11/12/21 Morgan Stanley Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update 11/09/21 Barclays Arcus Biosciences price target raised to $48 from $45 at Barclays 11/09/21 Mizuho Arcus Biosciences price target raised to $51 from $43 at Mizuho 10/19/21 Cowen Gilead assumed with an Outperform at Cowen GRCL Gracell $10.87 / -0.36 (-3.21%) 06/14/21 Piper Sandler Gracell plans to expand GC012F's clinical profile, says Piper Sandler 06/07/21 Citi Gracell valuation provides attractive entry point, says Citi 06/04/21 Piper Sandler Piper sees 'clear line of sight for value creation' at Gracell after ASCO 04/30/21 Piper Sandler Gracell transferred with Overweight rating at Piper Sandler HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) 10/27/21 Roth Capital Harpoon Therapeutics appoints new CEO, Roth Capital expects 'smooth transition' 09/27/21 Citi Harpoon Therapeutics upgraded to Buy from Neutral at Citi 08/06/21 Piper Sandler Harpoon Therapeutics price target lowered to $30 from $35 at Piper Sandler 07/12/21 Roth Capital Roth adds more 'SMID-cap' names to second half top picks IMAB I-Mab $60.16 / -0.85 (-1.39%) 09/03/21 Cantor Fitzgerald Cantor Fitzgerald positive on I-Mab following 'solid' first half 09/01/21 H.C. Wainwright I-Mab price target raised to $95 from $75 at H.C. Wainwright 07/26/21 Cantor Fitzgerald I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald 07/13/21 Cantor Fitzgerald I-Mab price target raised to $95 from $90 at Cantor Fitzgerald IMMP Immutep $4.27 / +0.27 (+6.75%) 08/03/21 Ladenburg Ladenburg starts Immutep with Buy into 'value-driving' events 08/03/21 Ladenburg Immutep initiated with a Buy at Ladenburg 07/16/21 Maxim Immutep assumed with a Buy at Maxim 06/10/21 Alliance Global Partners Immutep price target raised to $9 from $6 at Alliance Global Partners IMV IMV Inc. $1.55 / +0.01 (+0.65%) 09/22/21 Cantor Fitzgerald IMV Inc initiated with an Overweight at Cantor Fitzgerald 09/22/21 Cantor Fitzgerald IMV Inc. initiated with an Overweight at Cantor Fitzgerald 07/23/21 Wells Fargo IMV Inc. resumed with an Overweight at Wells Fargo 05/13/21 National Bank IMV Inc. price target lowered to C$4.25 from C$5.25 at National Bank IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 11/05/21 H.C. Wainwright Iovance Biotherapeutics price target lowered to $43 from $46 at H.C. Wainwright 11/05/21 Piper Sandler Iovance Biotherapeutics price target raised to $20 from $18 at Piper Sandler 06/29/21 H.C. Wainwright Iovance lung cancer data should improve with time, says H.C. Wainwright LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 11/11/21 Roth Capital aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital 10/12/21 RBC Capital aTyr Pharma initiated with an Outperform at RBC Capital 09/21/21 Piper Sandler aTyr Pharma initiated with an Overweight at Piper Sandler 09/14/21 Oppenheimer aTyr Pharma price target raised to $20 from $14 at Oppenheimer MRK Merck $84.02 / + (+0.00%) 11/05/21 Cowen Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen 11/01/21 Argus Merck upgraded to Buy from Hold at Argus 11/01/21 Argus Merck upgraded to Buy from Hold at Argus MRNA Moderna $231.26 / +5.3 (+2.35%) 11/12/21 Piper Sandler Piper keeps $348 target on Moderna after solid tumor data 11/08/21 Wolfe Research Moderna initiated with an Outperform at Wolfe Research 11/05/21 Jefferies Moderna price target lowered to $325 from $375 at Jefferies 11/05/21 Evercore ISI Denali Therapeutics price target raised to $111 from $70 at Evercore ISI SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 07/06/21 Piper Sandler Sensei Biotherapeutics price target lowered to $12 from $25 at Piper Sandler 07/05/21 AlphaValue/Baader Sensei Biotherapeutics downgraded to Add from Buy at AlphaValue 07/01/21 Berenberg Berenberg downgrades Sensei to Hold on 'significant setback' 07/01/21 Berenberg Sensei Biotherapeutics downgraded to Hold from Buy at Berenberg SGEN Seagen $178.94 / +1.395 (+0.79%) 11/08/21 Wolfe Research Seagen initiated with a Peer Perform at Wolfe Research 10/28/21 Piper Sandler Seagen price target raised to $165 from $160 at Piper Sandler 10/28/21 Piper Sandler Seagen price target raised to $165 from $160 at Piper Sandler 10/27/21 SVB Leerink Seagen price target raised to $200 from $190 at SVB Leerink PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) 10/12/21 Piper Sandler Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler 08/31/21 Piper Sandler Poseida selloff a buying opportunity, says Piper Sandler 06/30/21 Piper Sandler Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler 06/23/21 Piper Sandler Piper says 'time to take a fresh look' at Poseida after CEO meeting ONCS OncoSec $1.75 / +0.03 (+1.74%) 10/14/21 BTIG OncoSec assumed with a Buy at BTIG 04/15/21 Alliance Global Partners OncoSec price target raised to $11 from $6.50 at Alliance Global Partners 03/25/21 Maxim OncoSec price target raised to $12 from $8 at Maxim ONCR Oncorus $6.01 / -5.195 (-46.38%) 11/12/21 Piper Sandler Piper would be 'aggressive buyers' of Oncorus after '177 data 'as good as hoped' 06/22/21 Piper Sandler Oncorus investor day 'incrementally positive,' says Piper Sandler 04/19/21 Piper Sandler Oncorus selloff has nothing to do with fundamentals, says Piper Sandler 03/16/21 Fly Intel: Top five analyst initiations NXTC NextCure $6.42 / -0.18 (-2.73%) 11/05/21 Piper Sandler NextCure's Phase II NC318 study continuing weekly dosing, says Piper Sandler 08/08/21 Piper Sandler NextCure price target lowered to $21 from $26 at Piper Sandler 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) 10/28/21 Baird Nurix Therapeutics price target raised to $49 from $46 at Baird 10/27/21 SVB Leerink Nurix Therapeutics price target raised to $64 from $50 at SVB Leerink 10/27/21 Piper Sandler Nurix Phase I data 'incredibly encouraging,' says Piper Sandler 10/14/21 SVB Leerink Nurix Therapeutics initiated with an Outperform at SVB Leerink NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) 08/06/21 Fly Intel: Top five analyst initiations 08/06/21 Piper Sandler Neoleukin Therapeutics assumed with an Overweight at Piper Sandler 01/08/21 Piper Sandler Piper stays Overweight on Neoleukin after hold, sees 'laser-focused' response 01/05/21 Stifel Neoleukin Therapeutics initiated with a Buy at Stifel STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 04/14/21 Berenberg Shattuck Labs initiated with a Buy at Berenberg 01/20/21 Citi Shattuck Labs price target raised to $75 from $36 at Citi 01/11/21 Evercore ISI Shattuck Labs initiated with an Outperform at Evercore ISI TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 10/21/21 William Blair William Blair starts Tempest Therapeutics with buy on oncology assets 10/21/21 William Blair Tempest Therapeutics initiated with an Outperform at William Blair 07/13/21 Fly Intel: Top five analyst initiations 07/13/21 H.C. Wainwright Tempest Therapeutics initiated with a Buy at H.C. Wainwright ANCR Ancor Communications / + TPST STTK SNSE SGEN REGN PSTX ONCR NXTC NRIX NLTX MRNA MRK LIFE IOVA HARP GRCL GILD FATE CRVS CRSP CGEN ARAV ALXO ALEX ACHL TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 11/10/21 Tempest Therapeutics reports Q3 EPS ($1.21), three estiamtes ($1.05) STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 11/09/21 Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024 11/09/21 Shattuck Labs reports Q3 EPS (41c), two estimates (44c) SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 11/09/21 Sensei Biotherapeutics reports Q3 EPS (32c), consensus (24c) 08/04/21 Sensei Biotherapeutics reports Q2 EPS (32c), consensus (29c) SGEN Seagen $178.94 / +1.395 (+0.79%) 10/28/21 Seagen reports Q3 EPS ($1.61), consensus (57c) 07/29/21 Seagen reports Q2 EPS (47c), consensus (60c) REGN Regeneron $631.22 / +4.71 (+0.75%) 11/04/21 Regeneron reports Q3 EPS $15.37, consensus $9.56 08/05/21 Regeneron reports Q2 EPS $25.80, consensus $17.69 PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) 11/09/21 Poseida Therapeutics reports Q3 EPS (68c), consensus (74c) 08/12/21 Poseida Therapeutics reports Q3 EPS (74c), consensus (63c) ONCR Oncorus $6.01 / -5.195 (-46.38%) 11/03/21 Oncorus sees cash, cash equivalents sufficient to fund operations into late 2023 11/03/21 Oncorus reports Q3 EPS 65c, three estimates (64c) 08/04/21 Oncorus reports Q2 EPS (60c), consensus (56c) NXTC NextCure $6.42 / -0.18 (-2.73%) 11/04/21 NextCure reports Q3 EPS (65c), consensus (67c) 08/05/21 NextCure reports Q2 EPS (65c), consensus (61c) NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) 07/13/21 Nurix Therapeutics reports Q2 EPS (60c) consensus (54c) NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) 11/04/21 Neoleukin Therapeutics reports Q3 EPS (28c) consensus (28c) MRNA Moderna $231.26 / +5.3 (+2.35%) 11/04/21 Moderna sees FY22 revenue $17B-$22B, consensus $20.08B 11/04/21 Moderna reports Q3 EPS $7.70, consensus $9.05 08/05/21 Moderna reports Q2 EPS $6.46, consensus $6.04 08/04/21 Notable companies reporting before tomorrow's open MRK Merck $84.02 / + (+0.00%) 10/28/21 Merck raises FY21 adjusted EPS view to $5.65-$5.70, consensus $5.77 10/28/21 Merck reports Q3 adjusted EPS $1.75, consensus $1.55 10/27/21 Notable companies reporting before tomorrow's open LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 11/10/21 aTyr Pharma reports Q3 EPS (42c), consensus (60c) 08/10/21 aTyr Pharma reports Q2 EPS (64c), consensus (51c) IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 11/04/21 Iovance Biotherapeutics reports Q3 EPS (53c), consensus (53c) HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) 11/10/21 Harpoon Therapeutics reports Q3 EPS (51c), consensus (52c) 08/05/21 Harpoon Therapeutics reports Q2 EPS (52c), consensus (43c) GRCL Gracell $10.87 / -0.36 (-3.21%) 08/17/21 Gracell reports Q2 EPS (4c), consensus (12c) 05/17/21 Gracell reports Q1 EPS (5c), consensus (21c) GILD Gilead $67.48 / +0.07 (+0.10%) 10/28/21 Gilead raises FY21 adjusted EPS view to $7.90-$8.10 from $6.90-$7.25 10/28/21 Gilead Sciences reports Q3 adjusted EPS $2.65, consensus $1.74 10/28/21 Notable companies reporting after market close 07/29/21 Gilead raises FY21 adjusted EPS view to $6.90-$7.25 from $6.75-$7.45 FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 11/04/21 Fate Therapeutics reports Q3 EPS (45c), consensus (58c) 08/04/21 Fate Therapeutics reports Q2 EPS (58c), consensus (53c) CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 11/01/21 Corvus Pharmaceuticals reports Q3 EPS (24c), consensus (26c) CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 11/03/21 Crispr Therapeutics reports Q3 EPS ($1.67), consensus ($1.76) 07/29/21 Crispr Therapeutics reports Q2 EPS $9.44, consensus $3.52 CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) ARAV Aravive $4.03 / +0.24 (+6.33%) 10/28/21 Aravive reports Q3 EPS (15c), consensus (46c) 08/05/21 Aravive reports Q2 EPS (35c), consensus (40c) ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 05/17/21 ALX Oncology reports Q1 EPS (35c), consensus (41c) ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) 11/04/21 Alexander & Baldwin reports Q3 core FFO 25c, consensus 20c 11/04/21 Alexander & Baldwin raises 2021 core FFO view to 88c-92c from 81c-87c ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 11/09/21 Achilles Therapeutics reports Q3 EPS (34c), consensus (48c) 08/10/21 Achilles Therapeutics reports Q2 EPS (45c), consensus (49c) 16 Sep 15 Jul 31 Mar 05 Mar 12 Feb 12 Feb 09 Feb 04 Feb 21 Jan 13 Jan 13 Jan 07 Jan 06 Jan 08 Jan 10 Dec REGN MRNA MRK LIFE IMAB GILD CGEN REGN Regeneron $631.22 / +4.71 (+0.75%) 05/16/21 COVID drugmakers sponsoring ads on TV, social media, WSJ reports MRNA Moderna $231.26 / +5.3 (+2.35%) 11/09/21 Moderna, NIH in dispute over vaccine patent rights, NY Times reports 10/27/21 Moderna CEO sees COVID shot being used for teens within weeks, Reuters says 10/21/21 CDC panel unanimously backs Moderna, J&J Covid boosters, CNBC reports 10/18/21 FDA may act this week on mix-and-match for COVID vaccines, NYT says MRK Merck $84.02 / + (+0.00%) 11/12/21 Biden to nominate Robert Califf to lead FDA, Politico reports 11/03/21 Democrats reach agreement to lower prescription prices, WSJ reports 10/14/21 White House close to nominating Robert Califf to head FDA, Washington Post says 10/12/21 Bristol-Myers decided against Acceleron buyout over price, Bloomberg reports LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 05/28/21 aTyr Pharma higher after TipRanks Financial Blog mention IMAB I-Mab $60.16 / -0.85 (-1.39%) 06/14/21 I-Mab in talks for Uliledlimab partnership, Bloomberg reports GILD Gilead $67.48 / +0.07 (+0.10%) 08/26/21 Court overturns Gilead's $1.2B patent loss to Bristol-Myers, Bloomberg reports 08/09/21 Gilead to require U.S. employees to get COVID-19 vaccine, Reuters reports CGEN Compugen $5.87 / -1.29 (-18.02%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says TPST SNSE SGEN REGN ONCS MRNA MRK IOVA IMMP GILD FATE CRVS CRSP CGEN ALXO ACHL TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 07/13/21 Fly Intel: Pre-market Movers SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 06/28/21 Fly Intel: After-Hours Movers 05/19/21 Fly Intel: After-Hours Movers SGEN Seagen $178.94 / +1.395 (+0.79%) 10/11/21 Starbucks upgrade, DraftKings initiation among today's top calls on Wall Street 10/06/21 Before the Move: Watch Bicycle Therapeutics ahead of new cancer data 09/20/21 Fly Intel: After-Hours Movers REGN Regeneron $631.22 / +4.71 (+0.75%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/08/21 Fly Intel: Pre-market Movers 11/05/21 Fly Intel: Pre-market Movers ONCS OncoSec $1.75 / +0.03 (+1.74%) 07/07/21 Wall Street in Fives - Must Read Lists for Wednesday 07/07/21 Wall Street in Fives - Must Read Lists at Midday 07/07/21 Fly Intel: Pre-market Movers 07/06/21 Fly Intel: After-Hours Movers MRNA Moderna $231.26 / +5.3 (+2.35%) 11/04/21 Wall Street in Fives - Must Read Lists for Thursday 11/04/21 Wall Street in Fives - Must Read Lists at Midday 11/04/21 Moderna plunges after cutting product sales outlook 11/04/21 Fly Intel: Pre-market Movers MRK Merck $84.02 / + (+0.00%) 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday 10/28/21 Wall Street in Fives - Must Read Lists for Thursday IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 06/29/21 Wall Street in Fives - Must Read Lists for Tuesday 06/29/21 Wall Street in Fives - Must Read Lists at Midday 06/10/21 Wall Street in Fives - Must Read Lists for Thursday 06/10/21 Wall Street in Fives - Must Read Lists at Midday IMMP Immutep $4.27 / +0.27 (+6.75%) 06/21/21 Fly Intel: Pre-market Movers GILD Gilead $67.48 / +0.07 (+0.10%) 10/29/21 Wall Street in Fives - Must Read Lists for Friday 10/29/21 Wall Street in Fives - Must Read Lists at Midday 10/28/21 Fly Intel: After-Hours Movers 09/22/21 Wall Street in Fives - Must Read Lists for Wednesday FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 08/20/21 Wall Street in Fives - Must Read Lists for Friday 08/20/21 Wall Street in Fives - Must Read Lists at Midday 08/19/21 Fly Intel: After-Hours Movers 06/04/21 Wall Street in Fives - Must Read Lists for Friday CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 07/15/21 Fly Intel: After-Hours Movers CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 10/13/21 Wall Street in Fives - Must Read Lists for Wednesday 10/13/21 Wall Street in Fives - Must Read Lists at Midday 10/12/21 Fly Intel: After-Hours Movers 06/28/21 Intellia Therapeutics shares jump on milestone for genome editing CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 10/18/21 Fly Insider: Agile Therapeutics, ALX Oncology amid week's notable insider trades ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 05/19/21 Stifel moves to sidelines as Iovance's situation 'gets messier' 11/16/21 2021 Virtual Healthcare Conference 11/17/21 STAT Summit 2021 12/01/21 45th Nasdaq Virtual Investor Conference 11/29/21 Compugen - CGEN 02/03/22 Merck - MRK 11/28/21 PDUFA Date for KEYTRUDA (Phase 3 KEYNOTE-355 Trial) 11/30/21 Antimicrobial Drugs Advisory Committee Meeting 12/04/21 PDUFA Date for KEYTRUDA (Phase Keynote-716 Trial) 12/10/21 PDUFA Date for Keytruda (Phase 3 Keynote 564 Trial) 12/21/21 PDUFA Date for Gefapixant 02/28/22 PDUFA Date for Lenacapavir 03/21/22 Extended PDUFA Date for Gefapixant 03/28/22 PDUFA Date for KEYTRUDA (Keynote 158 Trial) 04/13/22 PDUFA Date for REGEN-COV 12/06/21 Gracell 12/13/21 Regeneron Pharmaceuticals 12/14/21 Fate Therapeutics, Inc. TPST STTK REGN MRNA MRK LIFE IOVA IMMP GILD CRVS CRSP TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 06/28/21 Six new option listings and five option delistings on June 28th STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 11/10/21 Seventeen new option listings on November 10th REGN Regeneron $631.22 / +4.71 (+0.75%) 08/19/21 Early notable gainers among liquid option names on August 19th 08/17/21 Early notable gainers among liquid option names on August 17th 08/13/21 Early notable gainers among liquid option names on August 13th 06/16/21 Early notable gainers among liquid option names on June 16th MRNA Moderna $231.26 / +5.3 (+2.35%) 09/16/21 Early notable gainers among liquid option names on September 16th 09/09/21 Early notable gainers among liquid option names on September 9th 08/31/21 Early notable gainers among liquid option names on August 31st 08/25/21 Early notable gainers among liquid option names on August 25th MRK Merck $84.02 / + (+0.00%) 11/02/21 Merck call volume above normal and directionally bullish 10/04/21 Unusually active option classes on open October 4th 10/04/21 Notable open interest changes for October 4th 10/04/21 Unusual call flow in option market yesterday LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 10/15/21 aTyr Pharma put volume heavy and directionally bearish 10/08/21 aTyr Pharma call volume above normal and directionally bullish 09/21/21 aTyr Pharma call volume above normal and directionally bullish IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 06/25/21 Iovance Biotherapeutics put volume heavy and directionally bearish 06/24/21 Iovance Biotherapeutics call volume above normal and directionally bullish 06/10/21 Iovance Biotherapeutics call volume above normal and directionally bullish 06/04/21 Iovance Biotherapeutics call volume above normal and directionally bullish IMMP Immutep $4.27 / +0.27 (+6.75%) 06/03/21 Ten new option listings and two option delistings on June 3rd GILD Gilead $67.48 / +0.07 (+0.10%) 10/01/21 Gilead call volume above normal and directionally bullish 09/20/21 Gilead call volume above normal and directionally bullish 09/13/21 Gilead call volume above normal and directionally bullish 07/02/21 Gilead call volume above normal and directionally bullish CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 10/28/21 Corvus Pharmaceuticals options imply 9.9% move in share price post-earnings 09/22/21 Unusually active option classes on open September 22nd 09/21/21 Corvus Pharmaceuticals call volume above normal and directionally bullish CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 10/29/21 Crispr Therapeutics put volume heavy and directionally bearish 10/06/21 Sweep Call Buyers in Crispr Therapeutics
Conference/Events	Society for Immunotherapy of Cancer to hold annual meeting » 04:55 11/13/21 11/13 04:55 11/13/21 04:55 CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) , REGN Regeneron $631.22 / +4.71 (+0.75%) , ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) , ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) , ALXO ALX Oncology $45.94 / +2.07 (+4.72%) , ARAV Aravive $4.03 / +0.24 (+6.33%) , CGEN Compugen $5.87 / -1.29 (-18.02%) , CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) , FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) , GILD Gilead $67.48 / +0.07 (+0.10%) , GRCL Gracell $10.87 / -0.36 (-3.21%) , HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) , IMAB I-Mab $60.16 / -0.85 (-1.39%) , IMMP Immutep $4.27 / +0.27 (+6.75%) , IMV IMV Inc. $1.55 / +0.01 (+0.65%) , IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) , LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) , MRK Merck $84.02 / + (+0.00%) , MRNA Moderna $231.26 / +5.3 (+2.35%) , SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) , SGEN Seagen $178.94 / +1.395 (+0.79%) , PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) , ONCS OncoSec $1.75 / +0.03 (+1.74%) , ONCR Oncorus $6.01 / -5.195 (-46.38%) , NXTC NextCure $6.42 / -0.18 (-2.73%) , NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) , NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) , STTK Shattuck Labs $12.52 / -0.63 (-4.79%) , TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) , ANCR Ancor Communications / + SITC 2021 to be held in… SITC 2021 to be held in Washington, D.C. on November 10-14. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TPST STTK SNSE SGEN REGN PSTX ONCS ONCR NXTC NRIX NLTX MRNA MRK LIFE IOVA IMV IMMP IMAB HARP GRCL GILD FATE CRVS CRSP CGEN ARAV ALXO ALEX ACHL TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 11/12/21 Tempest Therapeutics presents data supporting dual mechanism of TPST-1495 11/08/21 Tempest Therapeutics announces issuance of patents for TPST-1495 09/20/21 Tempest Therapeutics doses first patient in randomized study of TPST-1120 09/13/21 Tempest Therapeutics enters into exclusive license agreement STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 11/09/21 Shattuck Labs announces preliminary clinical data from ongoing ARC trials 08/18/21 Codiak appoints Lini Pandite to board of directors 06/01/21 Shattuck Labs appoints Abhinav Shukla as CTO 05/17/21 Ecor1 Capital reports 7.9% passive stake in Shattuck Labs SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 11/12/21 Sensei Biotherapeutics presents preclinical data for SNS-101 11/09/21 Sensei Biotherapeutics expects cash to fund operations into 1H24 08/04/21 Sensei Biotherapeutics expects cash to fund operations into 1H of 2024 08/02/21 Sensei Biotherapeutics appoints Kristian Humer to its board of directors SGEN Seagen $178.94 / +1.395 (+0.79%) 10/28/21 Seagen reports Q3 Adcetris revenue $184.8M, Padcev revenue $95M 10/28/21 Seagen now sees FY Adcetris net product sales $700M-$710M 10/12/21 Seagen, Astellas Pharma complete patient enrollment for Cohort K of EV-103 trial 09/28/21 Seagen completes patient enrollment in MOUNTAINEER trial REGN Regeneron $631.22 / +4.71 (+0.75%) 11/12/21 Regeneron announces $3B share repurchase program 11/12/21 Roche announces Ronapreve approved by EC to treat, prevent COVID-19 11/12/21 Regeneron reports EC approves antibody cocktail to treat, prevent COVID-19 11/11/21 Regeneron: CHMP recommends EU approval of antibody cocktail to treat Covid PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) 10/13/21 Poseida Therapeutics announces new leadership appointments 10/12/21 Poseida Therapeutics enters research collaboration with Takeda Pharmaceutical 08/31/21 Poseida reports preliminary results from Phase 1 trial of P-PSMA-101 08/30/21 Poseida Therapeutics: FDA clears IND application for P-BCMA-ALLO1 ONCS OncoSec $1.75 / +0.03 (+1.74%) 10/20/21 OncoSec Chief Scientific Officer Chris Twitty, Ph.D., to step down 08/16/21 OncoSec establishes Leadership Committee, interim CEO stepping down 07/06/21 OncoSec announces agreement with Merck ONCR Oncorus $6.01 / -5.195 (-46.38%) 11/12/21 Oncorus sinks after data but Piper 'aggressive buyers on the open' 11/12/21 Oncorus report initial data from ongoing Phase 1 trial of ONCR-177 at SITC 2021 11/11/21 Oncorus announces exclusive licensing agreement with Gaeta Therapeutics 08/04/21 Oncorus sees cash, cash equivalents sufficient to fund operations into late 2023 NXTC NextCure $6.42 / -0.18 (-2.73%) 10/19/21 NextCure announces three new members of its SAB 10/04/21 NextCure appoints Ellen Feigal, Anne Borgman to board of directors 07/06/21 NextCure initiates NC762 trial 06/21/21 NextCure announces publication of NC410 preclinical data NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) 11/12/21 Nurix Therapeutics presents data from preclinical studies on NX-0255 11/12/21 Nurix Therapeutics announces IND clearance for DeTIL-0255 10/27/21 Nurix Therapeutics announces initial data from Phase 1a trial of NX-2127 09/30/21 Nurix Therapeutics expands board of directors with two additional appointments NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) 11/12/21 Neoleukin Therapeutics presents NL-201 preclinical data at SITC 2021 11/04/21 Neoleukin Therapeutics sees sufficient cash to fund operations into 2H23 09/29/21 Neoleukin Therapeutics to present data on NL-CVX1 at IDWeek 2021 09/09/21 Neoleukin Therapeutics appoints Bill Arthur as VP, head of research MRNA Moderna $231.26 / +5.3 (+2.35%) 11/12/21 Moderna reports interim data from Phase 1 clinical study of mRNA-2752 11/11/21 Moderna disagrees NIAID scientists co-invented mRNA sequence claims 11/10/21 Germany recommends Pfizer vaccine over Moderna for young, pregnant 11/09/21 Moderna files to expand CMA for COVID-19 vaccine to include children MRK Merck $84.02 / + (+0.00%) 11/11/21 Trevena appoints Patricia Drake as CCO, Yoder as CBO 11/11/21 Merck initiates Phase 3 study evaluating VERQUVO 11/10/21 Merck to supply 1.6M courses of molnupiravir to Japan for $1.2B upon approval 11/09/21 Merck, Ridgeback: U.S. to purchase 1.4M additional courses of molnupiravir LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 11/09/21 aTyr Pharma presents research on effects of ATYR2810 11/02/21 BriaCell appoints Gross to board, separately enters 6-month marketing contract 10/06/21 aTyr Pharma appoints Robert Ashworth as VP, regulatory affairs 09/13/21 aTyr Pharma announces positive data from Phase 1b/2a trial for ATYR1923 IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 11/12/21 Iovance Biotherapeutics announces clinical data for LN-145 at SITC 2021 meeting 11/09/21 Iovance Biotherapeutics announces clinical data from TIL cell therapy 09/23/21 Iovance Biotherapeutics initiates clinical supply of TIL cell therapy 06/29/21 Iovance Biotherapeutics reports clinical data for TIL therapy LN-145 IMV IMV Inc. $1.55 / +0.01 (+0.65%) 10/07/21 Immunotherapeutic capacity of IMV's DPX delivery platform featured at AACR 08/10/21 IMV Inc. announces final topline results from DeCidE1 08/04/21 IMV Inc. CEO Frederic Ors departs, Andrew Hall appointed interim CEO 06/11/21 Shareholder raises concerns over IMV Inc.'s outlook IMMP Immutep $4.27 / +0.27 (+6.75%) 11/09/21 Immutep reports data from final Phase IIb AIPAC study 11/02/21 Immutep granted Chinese patent for eftilagimod alpha 10/29/21 Immutep receives EMA scientific advice for further clinical development of efti 10/28/21 Immutep estimates cash reach into December 2023 IMAB I-Mab $60.16 / -0.85 (-1.39%) 11/10/21 Jumpcan to pay I-Mab RMB 224M upfront in eftansomatropin alfa partnership 11/08/21 I-Mab announces strategic collaboration with Roche Diagnostics 11/01/21 I-Mab appoints new CFO and new Chief Strategy Officer 10/26/21 I-Mab announces partnership with Sinopharm HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) 11/12/21 Harpoon Therapeutics presents data on TriTAC-XR T cell engager platform 10/26/21 Harpoon Therapeutics CEO Jerry McMahon to retire, Julie Eastland to succeed 09/23/21 Harpoon Therapeutics CFO buys 10.3K shares of common stock 06/04/21 Harpoon Therapeutics presents updated data for phase 1/2a trial for HPN424 GRCL Gracell $10.87 / -0.36 (-3.21%) 08/16/21 Gracell signs license agreement with FutureGen Biopharm 06/02/21 Gracell reschedules clinical update conference call 05/28/21 Gracell Biotechnologies Inc (ADS) trading resumes 05/28/21 Gracell Biotechnologies Inc (ADS) trading halted, volatility trading pause GILD Gilead $67.48 / +0.07 (+0.10%) 11/10/21 Gilead says Phase 2B Trodelvy study meets primary ORR endpoint 10/29/21 Gilead announces interim results from BICSTaR study 10/28/21 Gilead announces Trodelvy-Keytruda trial collaboration with Merck 10/26/21 Gilead and Merck to begin Phase 2 clinical study of islatravir and lenacapavir FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 11/09/21 Fate Therapeutics announces abstract highlighting FT538, FT573 11/04/21 Fate Therapeutics announces presentations at ASH annual meeting 10/01/21 Fate Therapeutics announces presentation at SITC annual meeting 09/15/21 Fate Therapeutics announces publication of FT538 preclinical data CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 11/12/21 Corvus Pharmaceuticals presents updated data from mupadolimab Phase 1/1b trial 10/27/21 Corvus' China partner Angel approved by China regulator to begin TCL study 10/25/21 Corvus Pharmaceuticals-licensed CPI-818 approved for clinical trials in China 09/22/21 Corvus Pharmaceuticals provides update on mupadolimab in viruses and tumors CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 10/14/21 Crispr Therapeutics appoints Brendan Smith as Chief Financial Officer 10/14/21 ARK Investment bought 678K shares of Crispr Therapeutics on Wednesday 10/12/21 Crispr announces updated results in trial of CTX110 for large B-cell lymphomas 10/12/21 Cathie Wood's ARK Investment bought 248K shares of Crispr Therapeutics on Monday CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial ARAV Aravive $4.03 / +0.24 (+6.33%) 11/12/21 Aravive announces preliminary data from Phase 1b of ABV-500 with cabozantinib 11/09/21 Aravive announces preliminary data from Phase 1b trial evaluating ABV-500 08/09/21 Aravive announces first patient dosed in Phase 1b/2 clinical trial of AVB-500 08/05/21 Aravive expects cash, cash equivalents to fund operations into H2 of 2022 ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 11/09/21 ALX Oncology announces updated data from ongoing ASPEN-01 clinical trial 11/04/21 ALX Oncology to present early clinical data from ASPEN-02 10/21/21 ALX Oncology doses first patient in ASPEN-05 study of evorpacept 10/07/21 ALX Oncology announces acquisition of ScalmiBio ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) 11/12/21 Alexander & Baldwin sells Kukui'ula residential development 07/27/21 Alexander & Baldwin raises quarterly dividend to 18c from 16c per share ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 11/12/21 Achilles Therapeutics presents data on cNeT from VELOS Process 2 manufacturing 11/09/21 Achilles Therapeutics expects cash to fund operations into 2H of 2023 10/22/21 Achilles Therapeutics presents data at ESGCT on company's MAP 10/12/21 Achilles Therapeutics joins the NA-ATTC consortium CRSP REGN ACHL ALEX ALXO ARAV CGEN CRVS FATE GILD GRCL HARP IMAB IMMP IMV IOVA LIFE MRK MRNA SNSE SGEN PSTX ONCS ONCR NXTC NRIX NLTX STTK TPST ANCR CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 11/08/21 Goldman Sachs Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs 11/04/21 Raymond James ASH abstracts justify Crispr Therapeutics concerns, says Raymond James 11/04/21 Oppenheimer Crispr Therapeutics price target lowered to $172 from $185 at Oppenheimer 10/19/21 SVB Leerink Crispr Therapeutics initiated with an Outperform at SVB Leerink REGN Regeneron $631.22 / +4.71 (+0.75%) 11/10/21 Cantor Fitzgerald Regeneron price target raised to $760 from $700 at Cantor Fitzgerald 11/09/21 Benchmark Benchmark sees signs Regeneron may be planning large acquisition 11/05/21 Fly Intel: Top five analyst downgrades 11/05/21 Benchmark Regeneron downgraded to Hold from Buy at Benchmark ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 11/12/21 Piper Sandler Achilles provides clinical update for ATL001 trials, says Piper Sandler 08/10/21 Piper Sandler Achilles Therapeutics price target lowered to $23 from $25 at Piper Sandler 06/29/21 Chardan Iovance data show activity but 'not a home run,' says Chardan 05/19/21 Chardan Iovance Biotherapeutics price target lowered to $51 from $54 at Chardan ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) 07/30/21 Piper Sandler Alexander & Baldwin upgraded to Overweight from Neutral at Piper Sandler 12/23/20 Piper Sandler Alexander & Baldwin price target raised to $17 from $13 at Piper Sandler ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 11/09/21 Piper Sandler ALX Oncology price target lowered to $85 from $97 at Piper Sandler 11/09/21 H.C. Wainwright H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity 11/04/21 Piper Sandler ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler 09/29/21 Stifel ALX Oncology initiated with a Buy at Stifel ARAV Aravive $4.03 / +0.24 (+6.33%) 11/09/21 Piper Sandler Aravive data show preliminary efficacy in ccRCC, says Piper Sandler 08/06/21 Piper Sandler Aravive price target lowered to $18 from $20 at Piper Sandler 04/27/21 Piper Sandler Aravive doses first patient in Phase III AVB-500 trial, says Piper Sandler 03/08/21 Fly Intel: Top five analyst initiations CGEN Compugen $5.87 / -1.29 (-18.02%) CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 09/22/21 Roth Capital Corvus recent rally due to AstraZeneca data, says Roth Capital 08/03/21 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald 08/03/21 Mizuho Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho 07/16/21 H.C. Wainwright Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 11/08/21 Citi Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations 11/08/21 Citi Fate Therapeutics upgraded to Buy from Neutral at Citi 11/05/21 Roth Capital Fate Therapeutics price target lowered to $60 from $90 at Roth Capital 08/26/21 Fly Intel: Top five analyst initiations GILD Gilead $67.48 / +0.07 (+0.10%) 11/12/21 Morgan Stanley Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update 11/09/21 Barclays Arcus Biosciences price target raised to $48 from $45 at Barclays 11/09/21 Mizuho Arcus Biosciences price target raised to $51 from $43 at Mizuho 10/19/21 Cowen Gilead assumed with an Outperform at Cowen GRCL Gracell $10.87 / -0.36 (-3.21%) 06/14/21 Piper Sandler Gracell plans to expand GC012F's clinical profile, says Piper Sandler 06/07/21 Citi Gracell valuation provides attractive entry point, says Citi 06/04/21 Piper Sandler Piper sees 'clear line of sight for value creation' at Gracell after ASCO 04/30/21 Piper Sandler Gracell transferred with Overweight rating at Piper Sandler HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) 10/27/21 Roth Capital Harpoon Therapeutics appoints new CEO, Roth Capital expects 'smooth transition' 09/27/21 Citi Harpoon Therapeutics upgraded to Buy from Neutral at Citi 08/06/21 Piper Sandler Harpoon Therapeutics price target lowered to $30 from $35 at Piper Sandler 07/12/21 Roth Capital Roth adds more 'SMID-cap' names to second half top picks IMAB I-Mab $60.16 / -0.85 (-1.39%) 09/03/21 Cantor Fitzgerald Cantor Fitzgerald positive on I-Mab following 'solid' first half 09/01/21 H.C. Wainwright I-Mab price target raised to $95 from $75 at H.C. Wainwright 07/26/21 Cantor Fitzgerald I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald 07/13/21 Cantor Fitzgerald I-Mab price target raised to $95 from $90 at Cantor Fitzgerald IMMP Immutep $4.27 / +0.27 (+6.75%) 08/03/21 Ladenburg Ladenburg starts Immutep with Buy into 'value-driving' events 08/03/21 Ladenburg Immutep initiated with a Buy at Ladenburg 07/16/21 Maxim Immutep assumed with a Buy at Maxim 06/10/21 Alliance Global Partners Immutep price target raised to $9 from $6 at Alliance Global Partners IMV IMV Inc. $1.55 / +0.01 (+0.65%) 09/22/21 Cantor Fitzgerald IMV Inc initiated with an Overweight at Cantor Fitzgerald 09/22/21 Cantor Fitzgerald IMV Inc. initiated with an Overweight at Cantor Fitzgerald 07/23/21 Wells Fargo IMV Inc. resumed with an Overweight at Wells Fargo 05/13/21 National Bank IMV Inc. price target lowered to C$4.25 from C$5.25 at National Bank IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 11/05/21 H.C. Wainwright Iovance Biotherapeutics price target lowered to $43 from $46 at H.C. Wainwright 11/05/21 Piper Sandler Iovance Biotherapeutics price target raised to $20 from $18 at Piper Sandler 06/29/21 H.C. Wainwright Iovance lung cancer data should improve with time, says H.C. Wainwright LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 11/11/21 Roth Capital aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital 10/12/21 RBC Capital aTyr Pharma initiated with an Outperform at RBC Capital 09/21/21 Piper Sandler aTyr Pharma initiated with an Overweight at Piper Sandler 09/14/21 Oppenheimer aTyr Pharma price target raised to $20 from $14 at Oppenheimer MRK Merck $84.02 / + (+0.00%) 11/05/21 Cowen Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen 11/01/21 Argus Merck upgraded to Buy from Hold at Argus 11/01/21 Argus Merck upgraded to Buy from Hold at Argus MRNA Moderna $231.26 / +5.3 (+2.35%) 11/12/21 Piper Sandler Piper keeps $348 target on Moderna after solid tumor data 11/08/21 Wolfe Research Moderna initiated with an Outperform at Wolfe Research 11/05/21 Jefferies Moderna price target lowered to $325 from $375 at Jefferies 11/05/21 Evercore ISI Denali Therapeutics price target raised to $111 from $70 at Evercore ISI SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 07/06/21 Piper Sandler Sensei Biotherapeutics price target lowered to $12 from $25 at Piper Sandler 07/05/21 AlphaValue/Baader Sensei Biotherapeutics downgraded to Add from Buy at AlphaValue 07/01/21 Berenberg Berenberg downgrades Sensei to Hold on 'significant setback' 07/01/21 Berenberg Sensei Biotherapeutics downgraded to Hold from Buy at Berenberg SGEN Seagen $178.94 / +1.395 (+0.79%) 11/08/21 Wolfe Research Seagen initiated with a Peer Perform at Wolfe Research 10/28/21 Piper Sandler Seagen price target raised to $165 from $160 at Piper Sandler 10/28/21 Piper Sandler Seagen price target raised to $165 from $160 at Piper Sandler 10/27/21 SVB Leerink Seagen price target raised to $200 from $190 at SVB Leerink PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) 10/12/21 Piper Sandler Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler 08/31/21 Piper Sandler Poseida selloff a buying opportunity, says Piper Sandler 06/30/21 Piper Sandler Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler 06/23/21 Piper Sandler Piper says 'time to take a fresh look' at Poseida after CEO meeting ONCS OncoSec $1.75 / +0.03 (+1.74%) 10/14/21 BTIG OncoSec assumed with a Buy at BTIG 04/15/21 Alliance Global Partners OncoSec price target raised to $11 from $6.50 at Alliance Global Partners 03/25/21 Maxim OncoSec price target raised to $12 from $8 at Maxim ONCR Oncorus $6.01 / -5.195 (-46.38%) 11/12/21 Piper Sandler Piper would be 'aggressive buyers' of Oncorus after '177 data 'as good as hoped' 06/22/21 Piper Sandler Oncorus investor day 'incrementally positive,' says Piper Sandler 04/19/21 Piper Sandler Oncorus selloff has nothing to do with fundamentals, says Piper Sandler 03/16/21 Fly Intel: Top five analyst initiations NXTC NextCure $6.42 / -0.18 (-2.73%) 11/05/21 Piper Sandler NextCure's Phase II NC318 study continuing weekly dosing, says Piper Sandler 08/08/21 Piper Sandler NextCure price target lowered to $21 from $26 at Piper Sandler 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist 03/05/21 Truist NextCure upgraded to Buy from Hold at Truist NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) 10/28/21 Baird Nurix Therapeutics price target raised to $49 from $46 at Baird 10/27/21 SVB Leerink Nurix Therapeutics price target raised to $64 from $50 at SVB Leerink 10/27/21 Piper Sandler Nurix Phase I data 'incredibly encouraging,' says Piper Sandler 10/14/21 SVB Leerink Nurix Therapeutics initiated with an Outperform at SVB Leerink NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) 08/06/21 Fly Intel: Top five analyst initiations 08/06/21 Piper Sandler Neoleukin Therapeutics assumed with an Overweight at Piper Sandler 01/08/21 Piper Sandler Piper stays Overweight on Neoleukin after hold, sees 'laser-focused' response 01/05/21 Stifel Neoleukin Therapeutics initiated with a Buy at Stifel STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 04/14/21 Berenberg Shattuck Labs initiated with a Buy at Berenberg 01/20/21 Citi Shattuck Labs price target raised to $75 from $36 at Citi 01/11/21 Evercore ISI Shattuck Labs initiated with an Outperform at Evercore ISI TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 10/21/21 William Blair William Blair starts Tempest Therapeutics with buy on oncology assets 10/21/21 William Blair Tempest Therapeutics initiated with an Outperform at William Blair 07/13/21 Fly Intel: Top five analyst initiations 07/13/21 H.C. Wainwright Tempest Therapeutics initiated with a Buy at H.C. Wainwright ANCR Ancor Communications / + TPST STTK SNSE SGEN REGN PSTX ONCR NXTC NRIX NLTX MRNA MRK LIFE IOVA HARP GRCL GILD FATE CRVS CRSP CGEN ARAV ALXO ALEX ACHL TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 11/10/21 Tempest Therapeutics reports Q3 EPS ($1.21), three estiamtes ($1.05) STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 11/09/21 Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024 11/09/21 Shattuck Labs reports Q3 EPS (41c), two estimates (44c) SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 11/09/21 Sensei Biotherapeutics reports Q3 EPS (32c), consensus (24c) 08/04/21 Sensei Biotherapeutics reports Q2 EPS (32c), consensus (29c) SGEN Seagen $178.94 / +1.395 (+0.79%) 10/28/21 Seagen reports Q3 EPS ($1.61), consensus (57c) 07/29/21 Seagen reports Q2 EPS (47c), consensus (60c) REGN Regeneron $631.22 / +4.71 (+0.75%) 11/04/21 Regeneron reports Q3 EPS $15.37, consensus $9.56 08/05/21 Regeneron reports Q2 EPS $25.80, consensus $17.69 PSTX Poseida Therapeutics $7.31 / +0.16 (+2.24%) 11/09/21 Poseida Therapeutics reports Q3 EPS (68c), consensus (74c) 08/12/21 Poseida Therapeutics reports Q3 EPS (74c), consensus (63c) ONCR Oncorus $6.01 / -5.195 (-46.38%) 11/03/21 Oncorus sees cash, cash equivalents sufficient to fund operations into late 2023 11/03/21 Oncorus reports Q3 EPS 65c, three estimates (64c) 08/04/21 Oncorus reports Q2 EPS (60c), consensus (56c) NXTC NextCure $6.42 / -0.18 (-2.73%) 11/04/21 NextCure reports Q3 EPS (65c), consensus (67c) 08/05/21 NextCure reports Q2 EPS (65c), consensus (61c) NRIX Nurix Therapeutics $34.10 / +1.03 (+3.11%) 07/13/21 Nurix Therapeutics reports Q2 EPS (60c) consensus (54c) NLTX Neoleukin Therapeutics $6.34 / -0.05 (-0.78%) 11/04/21 Neoleukin Therapeutics reports Q3 EPS (28c) consensus (28c) MRNA Moderna $231.26 / +5.3 (+2.35%) 11/04/21 Moderna sees FY22 revenue $17B-$22B, consensus $20.08B 11/04/21 Moderna reports Q3 EPS $7.70, consensus $9.05 08/05/21 Moderna reports Q2 EPS $6.46, consensus $6.04 08/04/21 Notable companies reporting before tomorrow's open MRK Merck $84.02 / + (+0.00%) 10/28/21 Merck raises FY21 adjusted EPS view to $5.65-$5.70, consensus $5.77 10/28/21 Merck reports Q3 adjusted EPS $1.75, consensus $1.55 10/27/21 Notable companies reporting before tomorrow's open LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 11/10/21 aTyr Pharma reports Q3 EPS (42c), consensus (60c) 08/10/21 aTyr Pharma reports Q2 EPS (64c), consensus (51c) 05/13/21 aTyr Pharma reports Q1 EPS (51c), consensus (32c) IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 11/04/21 Iovance Biotherapeutics reports Q3 EPS (53c), consensus (53c) HARP Harpoon Therapeutics $7.66 / -0.09 (-1.16%) 11/10/21 Harpoon Therapeutics reports Q3 EPS (51c), consensus (52c) 08/05/21 Harpoon Therapeutics reports Q2 EPS (52c), consensus (43c) GRCL Gracell $10.87 / -0.36 (-3.21%) 08/17/21 Gracell reports Q2 EPS (4c), consensus (12c) 05/17/21 Gracell reports Q1 EPS (5c), consensus (21c) GILD Gilead $67.48 / +0.07 (+0.10%) 10/28/21 Gilead raises FY21 adjusted EPS view to $7.90-$8.10 from $6.90-$7.25 10/28/21 Gilead Sciences reports Q3 adjusted EPS $2.65, consensus $1.74 10/28/21 Notable companies reporting after market close 07/29/21 Gilead raises FY21 adjusted EPS view to $6.90-$7.25 from $6.75-$7.45 FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 11/04/21 Fate Therapeutics reports Q3 EPS (45c), consensus (58c) 08/04/21 Fate Therapeutics reports Q2 EPS (58c), consensus (53c) CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 11/01/21 Corvus Pharmaceuticals reports Q3 EPS (24c), consensus (26c) CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 11/03/21 Crispr Therapeutics reports Q3 EPS ($1.67), consensus ($1.76) 07/29/21 Crispr Therapeutics reports Q2 EPS $9.44, consensus $3.52 CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) 05/13/21 Compugen reports Q1 EPS (12c), consensus (13c) ARAV Aravive $4.03 / +0.24 (+6.33%) 10/28/21 Aravive reports Q3 EPS (15c), consensus (46c) 08/05/21 Aravive reports Q2 EPS (35c), consensus (40c) ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 05/17/21 ALX Oncology reports Q1 EPS (35c), consensus (41c) ALEX Alexander & Baldwin $24.52 / -0.51 (-2.04%) 11/04/21 Alexander & Baldwin reports Q3 core FFO 25c, consensus 20c 11/04/21 Alexander & Baldwin raises 2021 core FFO view to 88c-92c from 81c-87c ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 11/09/21 Achilles Therapeutics reports Q3 EPS (34c), consensus (48c) 08/10/21 Achilles Therapeutics reports Q2 EPS (45c), consensus (49c) 16 Sep 15 Jul 31 Mar 05 Mar 12 Feb 12 Feb 09 Feb 04 Feb 21 Jan 13 Jan 13 Jan 07 Jan 06 Jan 08 Jan 10 Dec REGN MRNA MRK LIFE IMAB GILD CGEN REGN Regeneron $631.22 / +4.71 (+0.75%) 05/16/21 COVID drugmakers sponsoring ads on TV, social media, WSJ reports MRNA Moderna $231.26 / +5.3 (+2.35%) 11/09/21 Moderna, NIH in dispute over vaccine patent rights, NY Times reports 10/27/21 Moderna CEO sees COVID shot being used for teens within weeks, Reuters says 10/21/21 CDC panel unanimously backs Moderna, J&J Covid boosters, CNBC reports 10/18/21 FDA may act this week on mix-and-match for COVID vaccines, NYT says MRK Merck $84.02 / + (+0.00%) 11/12/21 Biden to nominate Robert Califf to lead FDA, Politico reports 11/03/21 Democrats reach agreement to lower prescription prices, WSJ reports 10/14/21 White House close to nominating Robert Califf to head FDA, Washington Post says 10/12/21 Bristol-Myers decided against Acceleron buyout over price, Bloomberg reports LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 05/28/21 aTyr Pharma higher after TipRanks Financial Blog mention IMAB I-Mab $60.16 / -0.85 (-1.39%) 06/14/21 I-Mab in talks for Uliledlimab partnership, Bloomberg reports GILD Gilead $67.48 / +0.07 (+0.10%) 08/26/21 Court overturns Gilead's $1.2B patent loss to Bristol-Myers, Bloomberg reports 08/09/21 Gilead to require U.S. employees to get COVID-19 vaccine, Reuters reports CGEN Compugen $5.87 / -1.29 (-18.02%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says TPST SNSE SGEN REGN ONCS MRNA MRK IOVA IMMP GILD FATE CRVS CRSP CGEN ALXO ACHL TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 07/13/21 Fly Intel: Pre-market Movers SNSE Sensei Biotherapeutics $9.61 / +1.01 (+11.74%) 06/28/21 Fly Intel: After-Hours Movers 05/19/21 Fly Intel: After-Hours Movers SGEN Seagen $178.94 / +1.395 (+0.79%) 10/11/21 Starbucks upgrade, DraftKings initiation among today's top calls on Wall Street 10/06/21 Before the Move: Watch Bicycle Therapeutics ahead of new cancer data 09/20/21 Fly Intel: After-Hours Movers REGN Regeneron $631.22 / +4.71 (+0.75%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/08/21 Fly Intel: Pre-market Movers 11/05/21 Fly Intel: Pre-market Movers ONCS OncoSec $1.75 / +0.03 (+1.74%) 07/07/21 Wall Street in Fives - Must Read Lists for Wednesday 07/07/21 Wall Street in Fives - Must Read Lists at Midday 07/07/21 Fly Intel: Pre-market Movers 07/06/21 Fly Intel: After-Hours Movers MRNA Moderna $231.26 / +5.3 (+2.35%) 11/04/21 Wall Street in Fives - Must Read Lists for Thursday 11/04/21 Wall Street in Fives - Must Read Lists at Midday 11/04/21 Moderna plunges after cutting product sales outlook 11/04/21 Fly Intel: Pre-market Movers MRK Merck $84.02 / + (+0.00%) 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday 10/28/21 Wall Street in Fives - Must Read Lists for Thursday IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 06/29/21 Wall Street in Fives - Must Read Lists for Tuesday 06/29/21 Wall Street in Fives - Must Read Lists at Midday 06/10/21 Wall Street in Fives - Must Read Lists for Thursday 06/10/21 Wall Street in Fives - Must Read Lists at Midday IMMP Immutep $4.27 / +0.27 (+6.75%) 06/21/21 Fly Intel: Pre-market Movers GILD Gilead $67.48 / +0.07 (+0.10%) 10/29/21 Wall Street in Fives - Must Read Lists for Friday 10/29/21 Wall Street in Fives - Must Read Lists at Midday 10/28/21 Fly Intel: After-Hours Movers 09/22/21 Wall Street in Fives - Must Read Lists for Wednesday FATE Fate Therapeutics $55.73 / -0.73 (-1.29%) 08/20/21 Wall Street in Fives - Must Read Lists for Friday 08/20/21 Wall Street in Fives - Must Read Lists at Midday 08/19/21 Fly Intel: After-Hours Movers 06/04/21 Wall Street in Fives - Must Read Lists for Friday CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 07/15/21 Fly Intel: After-Hours Movers CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 10/13/21 Wall Street in Fives - Must Read Lists for Wednesday 10/13/21 Wall Street in Fives - Must Read Lists at Midday 10/12/21 Fly Intel: After-Hours Movers 06/28/21 Intellia Therapeutics shares jump on milestone for genome editing CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday ALXO ALX Oncology $45.94 / +2.07 (+4.72%) 10/18/21 Fly Insider: Agile Therapeutics, ALX Oncology amid week's notable insider trades ACHL Achilles Therapeutics $6.17 / -0.29 (-4.49%) 05/19/21 Stifel moves to sidelines as Iovance's situation 'gets messier' 11/16/21 2021 Virtual Healthcare Conference 11/17/21 STAT Summit 2021 12/01/21 45th Nasdaq Virtual Investor Conference 11/13/21 Iovance Biotherapeutics - IOVA 11/29/21 Compugen - CGEN 02/03/22 Merck - MRK 11/28/21 PDUFA Date for KEYTRUDA (Phase 3 KEYNOTE-355 Trial) 11/30/21 Antimicrobial Drugs Advisory Committee Meeting 12/04/21 PDUFA Date for KEYTRUDA (Phase Keynote-716 Trial) 12/10/21 PDUFA Date for Keytruda (Phase 3 Keynote 564 Trial) 12/21/21 PDUFA Date for Gefapixant 02/28/22 PDUFA Date for Lenacapavir 03/21/22 Extended PDUFA Date for Gefapixant 03/28/22 PDUFA Date for KEYTRUDA (Keynote 158 Trial) 04/13/22 PDUFA Date for REGEN-COV 11/13/21 Compugen 12/06/21 Gracell 12/13/21 Regeneron Pharmaceuticals 12/14/21 Fate Therapeutics, Inc. TPST STTK REGN MRNA MRK LIFE IOVA IMMP GILD CRVS CRSP TPST Tempest Therapeutics $11.40 / -0.45 (-3.80%) 06/28/21 Six new option listings and five option delistings on June 28th STTK Shattuck Labs $12.52 / -0.63 (-4.79%) 11/10/21 Seventeen new option listings on November 10th REGN Regeneron $631.22 / +4.71 (+0.75%) 08/19/21 Early notable gainers among liquid option names on August 19th 08/17/21 Early notable gainers among liquid option names on August 17th 08/13/21 Early notable gainers among liquid option names on August 13th 06/16/21 Early notable gainers among liquid option names on June 16th MRNA Moderna $231.26 / +5.3 (+2.35%) 09/16/21 Early notable gainers among liquid option names on September 16th 09/09/21 Early notable gainers among liquid option names on September 9th 08/31/21 Early notable gainers among liquid option names on August 31st 08/25/21 Early notable gainers among liquid option names on August 25th MRK Merck $84.02 / + (+0.00%) 11/02/21 Merck call volume above normal and directionally bullish 10/04/21 Unusually active option classes on open October 4th 10/04/21 Notable open interest changes for October 4th 10/04/21 Unusual call flow in option market yesterday LIFE aTyr Pharma $8.74 / +0.08 (+0.92%) 10/15/21 aTyr Pharma put volume heavy and directionally bearish 10/08/21 aTyr Pharma call volume above normal and directionally bullish 09/21/21 aTyr Pharma call volume above normal and directionally bullish IOVA Iovance Biotherapeutics $21.16 / -2.345 (-9.98%) 06/25/21 Iovance Biotherapeutics put volume heavy and directionally bearish 06/24/21 Iovance Biotherapeutics call volume above normal and directionally bullish 06/10/21 Iovance Biotherapeutics call volume above normal and directionally bullish 06/04/21 Iovance Biotherapeutics call volume above normal and directionally bullish IMMP Immutep $4.27 / +0.27 (+6.75%) 06/03/21 Ten new option listings and two option delistings on June 3rd GILD Gilead $67.48 / +0.07 (+0.10%) 10/01/21 Gilead call volume above normal and directionally bullish 09/20/21 Gilead call volume above normal and directionally bullish 09/13/21 Gilead call volume above normal and directionally bullish 07/02/21 Gilead call volume above normal and directionally bullish CRVS Corvus Pharmaceuticals $4.18 / -0.285 (-6.39%) 10/28/21 Corvus Pharmaceuticals options imply 9.9% move in share price post-earnings 09/22/21 Unusually active option classes on open September 22nd 09/21/21 Corvus Pharmaceuticals call volume above normal and directionally bullish CRSP Crispr Therapeutics $89.14 / +1.14 (+1.30%) 10/29/21 Crispr Therapeutics put volume heavy and directionally bearish 10/06/21 Sweep Call Buyers in Crispr Therapeutics
Conference/Events	Compugen management to meet with Truist » 04:55 11/13/21 11/13 04:55 11/13/21 04:55 CGEN Compugen $5.87 / -1.29 (-18.02%) Group Breakfast Meeting… Group Breakfast Meeting with President Cohen-Dayag and CFO Krashin to be held in Washington, D.C. on November 13 hosted by Truist. ShowHide Related Items >><< Company News Earnings Periodicals On The Fly Events CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) 05/13/21 Compugen reports Q1 EPS (12c), consensus (13c) CGEN Compugen $5.87 / -1.29 (-18.02%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says CGEN Compugen $5.87 / -1.29 (-18.02%) 11/12/21 Wall Street in Fives - Must Read Lists for Friday 11/12/21 Wall Street in Fives - Must Read Lists at Midday 11/16/21 2021 Virtual Healthcare Conference 11/29/21 Compugen - CGEN 11/13/21 Compugen
On The Fly	Wall Street in Fives - Must Read Lists for Friday » 16:06 11/12/21 11/12 16:06 11/12/21 16:06 JNJ Johnson & Johnson $164.97 / +1.9 (+1.17%) , BKNG Booking Holdings $2,453.11 / -23.96 (-0.97%) , WRBY Warby Parker $58.38 / +4.905 (+9.17%) , RIDE Lordstown Motors $5.67 / -1.235 (-17.90%) , JAMF Jamf Holding $32.49 / -8.77 (-21.26%) , NVDA Nvidia $303.98 / +0.14 (+0.05%) , PENN Penn National $58.32 / +0.12 (+0.21%) , CZR Caesars $106.10 / +4.155 (+4.08%) , HPE HP Enterprise $14.66 / -1.28 (-8.03%) , LH LabCorp $297.46 / +10.57 (+3.68%) , SYNH Syneos Health $94.00 / -8.59 (-8.37%) , GE General Electric $107.53 / +0.555 (+0.52%) , RIVN Rivian Automotive $129.36 / +6.52 (+5.31%) , CONE CyrusOne $85.23 / +2.51 (+3.03%) , SRNE Sorrento Therapeutics $6.42 / +0.045 (+0.71%) , HYZN Hyzon Motors $7.17 / +0.875 (+13.90%) , NGD New Gold $1.76 / +0.145 (+9.01%) , PAGS PagSeguro Digital $35.40 / +1.38 (+4.06%) , CGEN Compugen $5.84 / -1.32 (-18.44%) , HEPS Hepsiburada $3.56 / -2.06 (-36.65%) , FB Facebook; also tag MVRS $340.00 / +12.27 (+3.74%) , CPNG Coupang $26.60 / -2.575 (-8.83%) , MAPS WM Technology $9.50 / -2.12 (-18.24%) , AZN AstraZeneca $58.87 / -4.03 (-6.41%) , BKKT Bakkt $24.43 / -1.75 (-6.68%) , BLNK Blink Charging $39.98 / +4.42 (+12.43%) , SMAR Smartsheet $72.69 / +4.18 (+6.10%) , FLUX Flux Power $6.14 / +0.03 (+0.49%) , SVRA Savara $1.14 / -0.02 (-1.72%) , LAZR Luminar $19.59 / -0.4 (-2.00%) , AMD AMD $147.96 / +2 (+1.37%) , XLNX Xilinx $213.52 / +4.69 (+2.25%) Get caught up quickly on… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options XLNX WRBY SYNH SVRA SRNE SMAR RIVN RIDE PENN PAGS NVDA NGD MAPS LH LAZR JNJ JAMF HYZN HPE HEPS GE FLUX FB CZR CPNG CONE CGEN BLNK BKNG BKKT AZN AMD XLNX Xilinx $213.52 / +4.69 (+2.25%) 08/25/21 STMicroelectronics, Xilinx collaborate to power radiation-hardened FPGAs 06/30/21 AMD granted unconditional approval from EU for Xilinx takeover 06/10/21 Xilinx acquires Silexica, terms undisclosed WRBY Warby Parker $58.38 / +4.905 (+9.17%) 11/12/21 Warby Parker reports Q3 active customers up 395,000, or 23%, to 2.15M 10/08/21 Warby Parker falls -5.6% SYNH Syneos Health $94.00 / -8.59 (-8.37%) 10/13/21 ObsEva announces relationship with Syneos Health to commercialize linzagolix 10/06/21 Syneos Health acquires RxDataScience, terms not disclosed 09/14/21 Syneos Health to acquire StudyKIK 09/09/21 Syneos Health and Ride Health partner for clinical trial recruitment solutions SVRA Savara $1.14 / -0.02 (-1.72%) 06/30/21 Savara announces first patient dosed in Phase 3 aPAP trial SRNE Sorrento Therapeutics $6.42 / +0.045 (+0.71%) 11/12/21 Sorrento Therapeutics announces publication of trial results of abivertinib 11/03/21 Sorrento Therapeutics receives ANVISA approval for COVISTIX in Brazil 11/01/21 Sorrento Therapeutics announces license partner submitted NDA for socazolimab 10/27/21 Sorrento reports 'positive' preliminary results from Phase 2 Abivertinib studies SMAR Smartsheet $72.69 / +4.18 (+6.10%) 11/12/21 Smartsheet chief product officer Gene Farrell to depart, Praerit Garg to succeed 11/11/21 Smartsheet, McLaren Racing in new partnership for McLaren Formula 1 team 09/08/21 Smartsheet falls -10.3% 09/08/21 Smartsheet falls -13.2% RIVN Rivian Automotive $129.36 / +6.52 (+5.31%) 11/12/21 On Rivian, Musk says 'true test' is high production, cash flow breakeven 11/08/21 Rivian Automotive to begin RCV deliveries in early 2023 11/07/21 Fly Intel: Top five weekend stock stories 10/29/21 Amazon discloses 20% stake in electric vehicle marker Rivian RIDE Lordstown Motors $5.67 / -1.235 (-17.90%) 11/12/21 Lordstown delays Endurance deliveries to Q3 of 2022 11/11/21 Lordstown Motors sees FY21 capital expenditures $330M-$350M 11/10/21 Lordstown, Foxconn enter into definitive purchase agreement over Ohio facility 11/10/21 Lordstown Motors, Foxconn enter into strategic partnership PENN Penn National $58.32 / +0.12 (+0.21%) 11/11/21 Penn National up after Portnoy tweet on 'exposing Business Insider hit piece' 11/11/21 Penn National up 5% in afternoon trading 11/04/21 Barstiool's Dave Portnoy calls Business Insider story 'hit piece' 11/04/21 Penn National doesn't think any operator willl make money in New York PAGS PagSeguro Digital $35.40 / +1.38 (+4.06%) 10/28/21 PagSeguro Digital says company has no agreement with Pax Technology 10/15/21 PagSeguro sees 'negligible' impact to 2022 revenue, income from BCB hearing 10/11/21 PagSeguro Digital falls -11.5% 10/11/21 PagSeguro Digital falls -8.7% NVDA Nvidia $303.98 / +0.14 (+0.05%) 11/09/21 Luminar surges after lidar selected for Nvidia autonomous vehicle platform 11/08/21 AMD up over 10% after announcing Meta as data center chip customer 10/27/21 EU opens in-depth probe into proposed Nvidia-Arm deal 10/21/21 Nvidia announces GeForce NOW cloud gaming platform NGD New Gold $1.76 / +0.145 (+9.01%) 10/13/21 New Gold reports Q3 production 105,628 gold equivalent ounces 09/13/21 New Gold provides update on Rainy River Mine, consolidated operational outlook 05/25/21 New Gold receives Mines Act permit MAPS WM Technology $9.50 / -2.12 (-18.24%) 09/14/21 WM Technology acquires Sprout CRM and marketing platform 08/19/21 Weedmaps announces multiyear partnership with Kevin Durant, Thirty Five Ventures 08/18/21 Weedmaps teases 'changing the game' news for August 19 06/16/21 Weedmaps owner completes combination with Silver Spike Acquisition LH LabCorp $297.46 / +10.57 (+3.68%) 11/02/21 Boston, Ovia Health launch programs to improve maternal health outcomes 10/01/21 LabCorp receive EUA from FDA for home collection kit for COVID-19, flu detection 09/02/21 LabCorp raises minimum hourly wage to $15 per hour 08/16/21 Jana buys Cornerstone, cuts Conagra stake in Q2 LAZR Luminar $19.59 / -0.4 (-2.00%) 09/07/21 Luminar-equipped Mobileye Drive marks culmination of collaboration, company says 08/19/21 Luminar announces Munir Hafez joins company as CIO 07/19/21 Luminar acquires lidar chip partner OptoGration amid Iris scale into OEMs JNJ Johnson & Johnson $164.97 / +1.9 (+1.17%) 11/12/21 J&J understands 'historical significance' of separation, CEO Gorsky says 11/12/21 Johnson & Johnson has appetite for tuck-in M&A deals 11/12/21 AC Immune announces interim Phase 1b/2a data on ACI-35.030 11/12/21 Johnson & Johnson announces intent to separate Consumer Health business JAMF Jamf Holding $32.49 / -8.77 (-21.26%) 11/10/21 Jamf Holding down over 10% after Apple announces 'business essentials' launch 09/27/21 Jamf Holding appoints Linh Lam as CIO 08/10/21 Jamf Holding has identified an immaterial error related to commissions 07/01/21 Jamf Holding completes acquisition of Wandera HYZN Hyzon Motors $7.17 / +0.875 (+13.90%) 11/12/21 Hyzon Motors expects to ship 85 vehicles before end of year 11/10/21 TC Energy, Hyzon Motors enter hydrogen modular production hub agreement 11/10/21 Hyzon Motors, TC Energy partner on modular hydrogen production hub development 11/09/21 Hyzon Motors and Itochu sign MoU to develop hydrogen supply chain strategies HPE HP Enterprise $14.66 / -1.28 (-8.03%) 09/14/21 HP Enterprise names Fidelma Russo as new Chief Technology Officer 09/01/21 HP Enterprise wins $2B GreenLake contract with National Security Agency 09/01/21 HP Enterprise builds research supercomputer for Japan's University of Hyogo 08/30/21 AMD EPYC processors picked by Argonne National Laboratory HEPS Hepsiburada $3.56 / -2.06 (-36.65%) 11/12/21 Hepsiburada announces joint performance advertising platform with Facebook GE General Electric $107.53 / +0.555 (+0.52%) 11/10/21 General Electric announces launch of debt tender offers 11/09/21 General Electric CEO says no asset sales planned ahead of split 11/09/21 General Electric jumps 8% to $117.00 after plan to form three public companies 11/09/21 General Electric to form three public companies FLUX Flux Power $6.14 / +0.03 (+0.49%) 11/12/21 Flux Power says supply chain disruptions continue 07/22/21 Flux Power announces order backlog of $13.7M FB Facebook; also tag MVRS $340.00 / +12.27 (+3.74%) 11/10/21 Mosseri says Instagram testing 'Take a Break' feature 11/09/21 Meta to remove certain ad targeting options 11/08/21 AMD launches accelerators and EPYC processors, confirms Meta as CPU customer CZR Caesars $106.10 / +4.155 (+4.08%) 11/08/21 Caesars selected for New York mobile sports wagering license 11/02/21 Caesars CEO says virus numbers have subsided, seeing increased demand 11/02/21 Caesars COO says confident in return of convention customer in Las Vegas in 2022 11/02/21 Caesars says Las Vegas demand strength remained exceptionally strong CPNG Coupang $26.60 / -2.575 (-8.83%) 10/25/21 Payoneer, Coupang partner to enable sellers to expand, sell in South Korea 08/11/21 Coupang reports active customers up 26% y/y to 17M 06/29/21 Coupang rises 13.6% 05/17/21 Tiger Global made Roblox a top holding during Q1, exited GSX CONE CyrusOne $85.23 / +2.51 (+3.03%) 11/12/21 CyrusOne up 2% to $84.24 after WSJ says near takeover deal 09/28/21 CyrusOne up 5% after Reuters says company exploring potential sale 07/28/21 CyrusOne names David Ferdman interim CEO CGEN Compugen $5.84 / -1.32 (-18.44%) 11/12/21 Compugen reports data from Phase 1 dose escalation monotherapy study of COM902 11/12/21 Compugen reports preliminary data comparing PVRIG to TIGIT and PD-1 11/12/21 Compugen reports results from Phase 1/2 triple combination dose escalation study 11/12/21 Compugen presents preliminary results from COM902 trial BLNK Blink Charging $39.98 / +4.42 (+12.43%) 11/08/21 Blink Charging 'applauds' $1.2T bipartisan infrastructure bill 11/03/21 Blink Charging awarded grant funds to deploy DC Fast Chargers in Michigan 10/07/21 Blink Charging announces sale of 64 charging stations to Rudy's Performance 10/05/21 Blink Charging's Blue Mobility expands BlueLA car sharing program BKNG Booking Holdings $2,453.11 / -23.96 (-0.97%) 11/12/21 Booking Holdings to acquire Getaroom for $1.2B 11/03/21 Booking Holdings CEO 'pleased' by 'another quarter of sequential improvement' 08/23/21 Open Table, Clear Secure announce partnership 08/13/21 Soros Capital buys Amazon, exits Netflix in Q2 BKKT Bakkt $24.43 / -1.75 (-6.68%) 11/05/21 Bakkt expands cryptocurrency offering to include ethereum 11/01/21 Bakkt falls -9.2% 10/27/21 Bakkt falls -11.4% 10/26/21 Bakkt falls -20.2% AZN AstraZeneca $58.87 / -4.03 (-6.41%) 11/03/21 Integral Molecular enters antibody license agreement with AstraZeneca 11/02/21 SAGA Diagnostics enters into an assay development agreement with AstraZeneca 11/01/21 AstraZeneca's treatment of eosinophilic gastritis gets FDA orphan designation 11/01/21 AstraZeneca's treatment of eosinophilic gastroenteritis gets orphan designation AMD AMD $147.96 / +2 (+1.37%) 11/10/21 AMD 's 3rd Gen AMD EPYC processors selected by IBM Cloud 11/04/21 AMD announces AMD Radeon PRO V620 GPU JNJ BKNG WRBY RIDE JAMF NVDA PENN CZR HPE LH SYNH GE RIVN CONE SRNE HYZN NGD PAGS CGEN HEPS FB CPNG MAPS AZN BKKT BLNK SMAR FLUX SVRA LAZR AMD XLNX JNJ Johnson & Johnson $164.97 / +1.9 (+1.17%) 11/09/21 Mizuho Alkermes price target lowered to $33 from $36 at Mizuho 11/08/21 Morgan Stanley Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight 10/20/21 Raymond James Johnson & Johnson price target lowered to $178 from $183 at Raymond James 10/20/21 Baird Intuitive Surgical price target raised to $370 from $350 at Baird BKNG Booking Holdings $2,453.11 / -23.96 (-0.97%) 11/10/21 Fly Intel: Top five analyst upgrades 11/10/21 Argus Booking Holdings upgraded to Buy from Hold at Argus 11/10/21 Argus Booking Holdings upgraded to Buy from Hold at Argus 11/08/21 Susquehanna Booking Holdings price target raised to $3100 from $2850 at Susquehanna WRBY Warby Parker $58.38 / +4.905 (+9.17%) 10/26/21 Citi Warby Parker initiated with a Buy at Citi 10/25/21 Fly Intel: Top five analyst initiations 10/25/21 Cowen Cowen starts 'disruptive' Warby Parker at Outperform 10/25/21 Evercore ISI Warby Parker initiated with an In Line at Evercore ISI RIDE Lordstown Motors $5.67 / -1.235 (-17.90%) 11/12/21 R.F. Lafferty R.F. Lafferty upgrades Lordstown to Hold on better odds for Endurance production 11/12/21 R.F. Lafferty Lordstown Motors upgraded to Hold from Sell at R.F. Lafferty 11/12/21 Fly Intel: Top five analyst downgrades 11/12/21 RBC Capital Lordstown Motors price target lowered to $4 from $5 at RBC Capital JAMF Jamf Holding $32.49 / -8.77 (-21.26%) 11/12/21 Piper Sandler Jamf selloff on Apple product a buying opportunity, says Piper Sandler 11/12/21 Barclays Jamf Holding shares to remain range-bound, says Barclays 11/10/21 Needham Needham sees Apple Business Essentials functionality competitive with Jamf Now 10/19/21 Needham Jamf Holding price target raised to $55 from $45 at Needham NVDA Nvidia $303.98 / +0.14 (+0.05%) 11/12/21 Wedbush Nvidia downgraded to Neutral on valuation at Wedbush 11/12/21 Wedbush Nvidia downgraded to Neutral from Outperform at Wedbush 11/11/21 Craig-Hallum Aeva Technologies price target lowered to $15 from $20 at Craig-Hallum PENN Penn National $58.32 / +0.12 (+0.21%) 11/12/21 Fly Intel: Top five analyst upgrades 11/12/21 Deutsche Bank Deutsche upgrades Penn National to Hold after stock underperformance 11/12/21 Deutsche Bank Penn National upgraded to Hold from Sell at Deutsche Bank 11/05/21 Jefferies Penn National price target lowered to $62 from $81 at Jefferies CZR Caesars $106.10 / +4.155 (+4.08%) 11/12/21 Fly Intel: Top five analyst initiations 11/12/21 B. Riley B. Riley starts 'mispriced empire' Caesars with Buy, $191 target 11/12/21 B. Riley Caesars initiated with a Buy at B. Riley 11/03/21 Morgan Stanley Caesars' sports betting share 'starting to impress,' says Morgan Stanley HPE HP Enterprise $14.66 / -1.28 (-8.03%) 11/11/21 Goldman Sachs HP Enterprise downgraded to Sell from Neutral at Goldman Sachs 10/06/21 Morgan Stanley HP Enterprise price target lowered to $16 from $18 at Morgan Stanley 09/03/21 Raymond James HP Enterprise price target raised to $22 from $20 at Raymond James 09/03/21 Wells Fargo HP Enterprise price target raised to $20 from $18 at Wells Fargo LH LabCorp $297.46 / +10.57 (+3.68%) 10/19/21 Citi Citi opens 'Positive Catalyst watches' on Quest, LabCorp 08/20/21 Credit Suisse LabCorp price target raised to $336 from $295 at Credit Suisse 08/19/21 Mizuho LabCorp price target raised to $332 from $318 at Mizuho 07/30/21 Truist LabCorp price target raised to $350 from $330 at Truist SYNH Syneos Health $94.00 / -8.59 (-8.37%) 11/04/21 Baird Syneos Health price target raised to $122 from $115 at Baird 11/04/21 Barclays Syneos Health upgraded to Overweight from Equal Weight at Barclays 08/04/21 Credit Suisse Syneos Health assumed with an Outperform at Credit Suisse 07/13/21 Barclays Syneos Health price target raised to $102 from $90 at Barclays GE General Electric $107.53 / +0.555 (+0.52%) 11/10/21 Wells Fargo General Electric price target raised to $120 from $110 at Wells Fargo 11/10/21 JPMorgan JPMorgan's Tusa sees fair value for GE shares under $70 11/09/21 Deutsche Bank General Electric upgraded to Buy at Deutsche Bank on updated sum-of-the-parts 11/09/21 Deutsche Bank General Electric upgraded to Buy from Hold at Deutsche Bank RIVN Rivian Automotive $129.36 / +6.52 (+5.31%) CONE CyrusOne $85.23 / +2.51 (+3.03%) 10/29/21 Deutsche Bank CyrusOne price target raised to $85 from $82 at Deutsche Bank 10/26/21 Evercore ISI CyrusOne initiated with an Outperform at Evercore ISI 10/20/21 Cowen Cowen upgrades CyrusOne to Outperform, sees takeover as 'imminent' 10/20/21 Cowen CyrusOne upgraded to Outperform from Market Perform at Cowen SRNE Sorrento Therapeutics $6.42 / +0.045 (+0.71%) 08/09/21 H.C. Wainwright Sorrento Therapeutics price target lowered to $26 from $30 at H.C. Wainwright 03/26/21 B. Riley Sorrento data make case for expedited EUA filing path, says B. Riley Securities 01/29/21 B. Riley Sorrento Therapeutics initiated with a Buy at B. Riley Securities 01/21/21 Alliance Global Partners Sorrento Therapeutics initiated with a Buy at Alliance Global Partners HYZN Hyzon Motors $7.17 / +0.875 (+13.90%) 10/19/21 Goldman Sachs Hyzon Motors initiated with a Neutral at Goldman Sachs 09/09/21 JPMorgan Hyzon Motors initiated with an Overweight at JPMorgan 08/31/21 Wedbush Hyzon Motors price target raised to $15 from $10 at Wedbush 08/13/21 Wedbush Wedbush starts hydrogen vehicle 'winner' Hyzon Motors at Outperform NGD New Gold $1.76 / +0.145 (+9.01%) 09/14/21 Canaccord New Gold price target lowered to C$2 from C$2.75 at Canaccord 09/14/21 BMO Capital New Gold price target lowered to C$3.25 from C$3.50 at BMO Capital 09/14/21 National Bank New Gold price target lowered to C$2 from C$2.50 at National Bank 09/14/21 Canaccord New Gold price target lowered to C$2.00 from C$2.75 at Canaccord PAGS PagSeguro Digital $35.40 / +1.38 (+4.06%) 11/12/21 Deutsche Bank PagSeguro Digital price target lowered to $58 from $70 at Deutsche Bank 10/18/21 Deutsche Bank PagSeguro concerns have no long-term impact, says Deutsche Bank 10/12/21 Goldman Sachs PagSeguro recent selloff may be overdone, says Goldman Sachs 10/11/21 Citi Brazil's proposed fee cap could remove 4% of PagSeguro revenue, says Citi CGEN Compugen $5.84 / -1.32 (-18.44%) HEPS Hepsiburada $3.56 / -2.06 (-36.65%) 08/31/21 Fly Intel: Top five analyst downgrades 08/31/21 BofA Hepsiburada downgraded to Neutral from Buy at BofA 08/04/21 Fly Intel: Top five analyst initiations 08/04/21 HSBC Hepsiburada initiated with a Buy at HSBC FB Facebook; also tag MVRS $340.00 / +12.27 (+3.74%) 11/09/21 Morgan Stanley Twitter price target lowered to $62 from $68 at Morgan Stanley 11/09/21 Susquehanna AMD price target raised to $175 from $145 at Susquehanna 11/08/21 Stifel AMD-Meta partnership shows secular growth thesis 'gaining momentum,' says Stifel 11/08/21 Wells Fargo AMD price target raised to $180 from $145 at Wells Fargo CPNG Coupang $26.60 / -2.575 (-8.83%) 10/12/21 Citi Coupang price target lowered to $32 from $39 at Citi 08/26/21 Daiwa Coupang upgraded to Buy on improving fundamentals at Daiwa 08/26/21 Daiwa Coupang upgraded to Buy from Outperform at Daiwa 08/12/21 Deutsche Bank Coupang upgraded to Buy after earnings at Deutsche Bank MAPS WM Technology $9.50 / -2.12 (-18.24%) 11/12/21 Truist WM Technology price target lowered to $15 from $18 at Truist 11/12/21 Piper Sandler WM Technology price target lowered to $14 from $16 at Piper Sandler 11/11/21 Benchmark Merida Merger Corp. I initiated with a Buy at Benchmark 09/14/21 Piper Sandler Piper says WM Technology improves software breadth with Sprout deal AZN AstraZeneca $58.87 / -4.03 (-6.41%) 10/27/21 SVB Leerink Seagen price target raised to $200 from $190 at SVB Leerink 10/19/21 UBS AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS 10/11/21 Deutsche Bank AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank 09/29/21 Stifel Zentalis initiated with a Buy at Stifel BKKT Bakkt $24.43 / -1.75 (-6.68%) 11/11/21 Fly Intel: Top five analyst initiations 11/11/21 Jefferies Jefferies starts Bakkt at Hold as more adoption 'proof-points' awaited 11/11/21 Jefferies Bakkt initiated with a Hold at Jefferies 11/02/21 Piper Sandler IntercontinentalExchange shares not reflecting positives, says Piper Sandler BLNK Blink Charging $39.98 / +4.42 (+12.43%) 11/12/21 Roth Capital Blink Charging upgraded to Buy from Neutral at Roth Capital 11/12/21 Roth Capital Blink Charging upgraded to Buy from Neutral at Roth Capital 11/12/21 Cowen Blink Charging price target raised to $41 from $35 at Cowen SMAR Smartsheet $72.69 / +4.18 (+6.10%) 09/08/21 BMO Capital Smartsheet price target raised to $90 from $78 at BMO Capital 09/08/21 Truist Smartsheet price target raised to $100 from $85 at Truist 09/08/21 Needham Smartsheet price target raised to $100 from $80 at Needham 09/08/21 KeyBanc Smartsheet price target raised to $94 from $86 at KeyBanc FLUX Flux Power $6.14 / +0.03 (+0.49%) 10/05/21 H.C. Wainwright Flux Power initiated with a Buy at H.C. Wainwright 09/28/21 Maxim Flux Power price target lowered to $13 from $15 at Maxim 05/12/21 Roth Capital Flux Power price target lowered to $13 from $20 at Roth Capital 02/04/21 Fly Intel: Top five analyst initiations SVRA Savara $1.14 / -0.02 (-1.72%) 09/10/21 Piper Sandler Piper 'even more bullish' on Savara study after management meeting 06/30/21 Piper Sandler Savara doses first patient in IMPALA-2 study, says Piper Sandler 05/24/21 Oppenheimer Oppenheimer says Savara should not be overlooked, ups target to $5 04/19/21 Piper Sandler Savara shares are trading below cash, says Piper Sandler LAZR Luminar $19.59 / -0.4 (-2.00%) 11/12/21 R.F. Lafferty Luminar price target lowered to $37 from $38 at R.F. Lafferty 06/25/21 Baird Baird upgrades Luminar to Outperform ahead of expected outlook hike 06/25/21 Baird Luminar upgraded to Outperform from Neutral at Baird AMD AMD $147.96 / +2 (+1.37%) 11/09/21 Wedbush AMD price target raised to $165 from $140 at Wedbush XLNX Xilinx $213.52 / +4.69 (+2.25%) 10/28/21 Truist Xilinx price target raised to $180 from $143 at Truist 10/28/21 Wells Fargo Xilinx price target raised to $190 from $140 at Wells Fargo 10/28/21 Deutsche Bank Xilinx price target raised to $195 from $155 at Deutsche Bank 10/28/21 Mizuho Xilinx price target raised to $200 from $150 at Mizuho XLNX WRBY SYNH SVRA SRNE SMAR RIDE PENN PAGS NVDA NGD MAPS LH LAZR JNJ JAMF HYZN HPE GE FLUX FB CZR CPNG CONE CGEN BLNK BKNG BKKT AZN AMD XLNX Xilinx $213.52 / +4.69 (+2.25%) 10/27/21 Xilinx reports Q2 adjusted EPS $1.06, consensus 87c 10/27/21 Notable companies reporting after market close 07/28/21 Xilinx reports Q1 adjusted EPS 95c, consensus 77c 07/28/21 Notable companies reporting after market close WRBY Warby Parker $58.38 / +4.905 (+9.17%) 11/12/21 Warby Parker raises FY21 revenue view to $539.5M-$542M, consensus $538.67M 11/12/21 Warby Parker reports Q3 adjusted EPS 3c, consensus (36c) 11/11/21 Notable companies reporting before tomorrow's open SYNH Syneos Health $94.00 / -8.59 (-8.37%) 11/03/21 Syneos Health raises FY21 adjusted EPS view to $4.35-$4.49 from $4.25-$4.43 11/03/21 Syneos Health reports Q3 adjusted EPS $1.22, consensus $1.17 08/09/21 Syneos Health raises FY21 adjusted EPS view to $4.25-$4.43 from $4.17-$4.42 08/09/21 Syneos Health reports Q2 adjusted EPS 97c, consensus 96c SVRA Savara $1.14 / -0.02 (-1.72%) 11/12/21 Savara reports Q3 EPS (7c), consensus (9c) 08/12/21 Savara reports Q EPS (7c), consensus (12c) 05/13/21 Savara reports Q1 EPS (13c), consensus (8c) SRNE Sorrento Therapeutics $6.42 / +0.045 (+0.71%) 08/09/21 Sorrento Therapeutics reports Q2 EPS (57c), two estimates (20c) SMAR Smartsheet $72.69 / +4.18 (+6.10%) 11/12/21 Smartsheet raises Q3 revenue view to $143.5M-$144.5M from $138M-$139M 09/07/21 Smartsheet backs FY22 EPS view (44c)-(36c), consensus (39c) 09/07/21 Smartsheet sees Q3 adjusted EPS (12c)-(10c), consensus (11c) 09/07/21 Smartsheet reports Q2 adjusted EPS (5c), consensus (13c) RIDE Lordstown Motors $5.67 / -1.235 (-17.90%) 11/11/21 Lordstown Motors reports Q3 EPS (54c), consensus (59c) 11/11/21 Notable companies reporting after market close 08/11/21 Lordstown Motors reports Q2 EPS (61c), consensus (46c) 08/11/21 Notable companies reporting after market close PENN Penn National $58.32 / +0.12 (+0.21%) 11/04/21 Penn National reports Q3 EPS 52c, consensus 89c 11/03/21 Notable companies reporting before tomorrow's open 08/05/21 Penn National reports Q2 EPS $1.17, consensus 90c PAGS PagSeguro Digital $35.40 / +1.38 (+4.06%) 11/12/21 PagSeguro Digital reports Q3 adjusted EPS R$1.26 vs. R$1.00 last year NVDA Nvidia $303.98 / +0.14 (+0.05%) 08/18/21 Nvidia sees Q3 revenue $6.8B, plus or minus 2%, consensus $6.53B 08/18/21 Nvidia reports Q2 gaming revenue $3.06B, up 85% y/y 08/18/21 Nvidia reports Q2 adjusted EPS $1.04, consensus $1.02 08/18/21 Notable companies reporting after market close NGD New Gold $1.76 / +0.145 (+9.01%) 11/12/21 New Gold reports Q3 adjusted EPS 3c, consensus 2c 08/11/21 New Gold reports Q2 adjusted EPS 4c, consensus 1c MAPS WM Technology $9.50 / -2.12 (-18.24%) 11/11/21 WM Technology sees Q4 revenue $50M-$52M, consensus $59.39M 11/11/21 WM Technology reports Q3 EPS 2c, consensus 1c LH LabCorp $297.46 / +10.57 (+3.68%) 10/28/21 LabCorp raises FY21 adjusted EPS view to $26-$28 from $25-$26 10/28/21 LabCorp reports Q3 adjusted EPS $6.82, consensus $4.92 07/29/21 LabCorp sees FY21 EPS $21.50-$25.00, consensus $22.54 07/29/21 LabCorp reports Q2 EPS $6.13, consensus $5.57 LAZR Luminar $19.59 / -0.4 (-2.00%) 11/11/21 Luminar reports Q3 adjusted EPS (10c), consensus (10c) 08/12/21 Luminar reports Q2 EPS (8c), consensus (7c) 05/13/21 Luminar reports Q1 EPS (11c), consensus (6c) 05/13/21 Luminar on track to achieve FY21 revenue $25M-$30M, consensus $27.95M JNJ Johnson & Johnson $164.97 / +1.9 (+1.17%) 10/19/21 Johnson & Johnson raises FY21 adjusted EPS view to $9.65-$9.70 from $9.50-$9.60 10/19/21 Johnson & Johnson reports Q3 adjusted EPS $2.60, consensus $2.35 10/18/21 Notable companies reporting before tomorrow's open JAMF Jamf Holding $32.49 / -8.77 (-21.26%) 11/11/21 Jamf Holding sees FY21 revenue $361.5M-$363.5M, consensus $359.61M 11/11/21 Jamf Holding sees Q4 revenue 99M-$101M, consensus $98.73M 11/11/21 Jamf Holding reports Q3 EPS (26c), consensus 1c HYZN Hyzon Motors $7.17 / +0.875 (+13.90%) 11/12/21 Hyzon Motors reports Q3 EPS 13c, consensus (8c) HPE HP Enterprise $14.66 / -1.28 (-8.03%) 10/28/21 HP Enterprise sees compound annual revenue growth rate of 2-4% in FY22-FY24 10/28/21 HP Enterprise sees FY22 revenue growth to be 3-4% in constant currency 10/28/21 HP Enterprise sees FY22 non-GAAP EPS $1.96-$2.10, consensus $1.98 09/02/21 HP Enterprise raises FY21 adjusted EPS view to $1.88-$1.96, consensus $1.89 GE General Electric $107.53 / +0.555 (+0.52%) 10/26/21 General Electric sees FY21 revenue 'about flat,' consensus $76.7B 10/26/21 General Electric raises FY21 adjusted EPS view to $1.80-$2.10 from $1.20-$2.00 10/26/21 General Electric reports Q3 adjusted EPS 57c, consensus 43c 10/25/21 Notable companies reporting before tomorrow's open FLUX Flux Power $6.14 / +0.03 (+0.49%) 11/12/21 Flux Power reports Q1 EPS (30c), consensus (28c) 05/13/21 Flux Power reports Q3 EPS (14c), consensus (24c) FB Facebook; also tag MVRS $340.00 / +12.27 (+3.74%) 10/25/21 Facebook reports Q3 EPS $3.22, consensus $3.19 10/25/21 Facebook sees Q4 revenue of $31.5B-$34B, consensus $34.89B 10/25/21 Notable companies reporting after market close 09/30/21 Amazon settles with influencers 'who ran social media counterfeiting scheme' CZR Caesars $106.10 / +4.155 (+4.08%) 11/09/21 Caesars Sportsbook signs the Mannings sports family 11/02/21 Caesars reports Q3 cont ops EPS ($1.08), consensus 18c 11/02/21 Notable companies reporting after market close 08/03/21 Caesars reports Q2 EPS 34c, consensus (26c) CPNG Coupang $26.60 / -2.575 (-8.83%) 11/12/21 Coupang reports Q3 EPS (19c), consensus (17c) 08/11/21 Coupang reports Q2 EPS (30c), consensus (14c) 05/12/21 Coupang reports Q1 EPS (68c) vs. ($5.74) last year. CONE CyrusOne $85.23 / +2.51 (+3.03%) 10/27/21 CyrusOne raises FY21 normalized FFO $4.03-$4.08 from $3.95-$4.05 10/27/21 CyrusOne reports Q3 normalized FFO $1.02, consensus 99c 07/28/21 CyrusOne raises FY21 normalized FFO view to $3.95-$4.05 from $3.90-$4 07/28/21 CyrusOne reports Q2 normalized FFO $1.00, consensus 98c CGEN Compugen $5.84 / -1.32 (-18.44%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) 05/13/21 Compugen reports Q1 EPS (12c), consensus (13c) BLNK Blink Charging $39.98 / +4.42 (+12.43%) 11/11/21 Blink Charging reports Q3 EPS (36c), consensus (29c) 08/11/21 Blink Charging reports Q2 EPS (32c), consensus (16c) 05/13/21 Blink Charging reports Q1 EPS (18c), consensus (17c) BKNG Booking Holdings $2,453.11 / -23.96 (-0.97%) 11/03/21 Booking Holdings says Q4 revenue to decline more from Q3 than in 2019 11/03/21 Booking Holdings reports Q3 adjusted EPS $37.70, consensus $32.90 11/03/21 Notable companies reporting after market close 08/04/21 Booking Holdings reports Q2 adjusted EPS ($2.55), consensus ($2.10) BKKT Bakkt $24.43 / -1.75 (-6.68%) 11/12/21 Bakkt reports Q3 revenue $9.1M vs. $6.6M last year AZN AstraZeneca $58.87 / -4.03 (-6.41%) 11/12/21 AstraZeneca backs FY21 core EPS view of $5.05-$5.40, consensus $3.27 11/12/21 AstraZeneca reports Q3 core EPS $1.08, two estimates 62c 07/29/21 AstraZeneca sees FY21 core EPS $5.05-$5.40, consensus $5.14 AMD AMD $147.96 / +2 (+1.37%) 10/26/21 AMD sees FY21 revenue growth of approximately 65% 10/26/21 AMD sees Q4 revenue $4.5B, +/- $100M, consensus $4.25B 10/26/21 AMD reports Q3 EPS 73c, consensus 67c 10/26/21 Notable companies reporting after market close 10 Nov 14 Sep 29 Sep 29 Jun 01 Jul 10 Jun 03 Jun 04 May 11 Mar 11 Mar 01 Mar 08 Jan 02 Dec 19 Nov RIVN RIDE PENN PAGS NVDA LH LAZR JNJ HPE GE FB CZR CPNG CONE CGEN BLNK BKNG AZN AMD RIVN Rivian Automotive $129.36 / +6.52 (+5.31%) 11/12/21 Rivian pursuing site for U.S. standalone battery factory, Bloomberg reports 11/09/21 Rivian Automotive expanding IPO size to 153M shares from 135M, Bloomberg says 11/06/21 A $64B valuation for Rivian 'isn't crazy,' Barron's says 11/01/21 Rivian targets IPO valuation just above $60B in IPO next week, WSJ says RIDE Lordstown Motors $5.67 / -1.235 (-17.90%) 10/08/21 Foxconn to produce Lordstown's Endurance electric truck, DigiTimes reports 09/30/21 Lordstown nearing deal to sell Ohio plant to Foxconn, Bloomberg reports 09/28/21 Blue Orca says short Hyzon Motors, likens to 'a Chinese Lordstown Motors' 09/01/21 SEC opens investigation into electric delivery-truck maker Workhorse, WSJ says PENN Penn National $58.32 / +0.12 (+0.21%) 11/08/21 Group with Barstool out of running for NY sports betting license, NY Post says 11/05/21 Prescience Point says long Penn National, sees 'huge dislocation' 11/04/21 Penn National falls after BI details allegations against Dave Portnoy 08/19/21 North Carolina Senate approves sports betting bill, iGB reports PAGS PagSeguro Digital $35.40 / +1.38 (+4.06%) 10/27/21 Viceroy says short StoneCo and PagSeguro after FBI raid on PAX Global 10/27/21 PagSeguro Digital, StoneCo named as short ideas by Viceroy Research NVDA Nvidia $303.98 / +0.14 (+0.05%) 10/27/21 CFTC head wants to police crypto market in challenge to SEC, Market Insider says 10/27/21 Samsung working on cloud gaming platform for Smart TVs, IGN says 10/12/21 Semi shortage hurts manufacturers, 'not great for chip makers either,' WSJ says 10/12/21 Nvidia concessions to EU failed to address competition concerns, Reuters says LH LabCorp $297.46 / +10.57 (+3.68%) 11/12/21 LabCorp in talks to combine some assets with Syneos, Bloomberg reports LAZR Luminar $19.59 / -0.4 (-2.00%) 06/24/21 Luminar CFO aims to increase production, conserve cash, WSJ reports 05/24/21 Tesla testing Luminar Technologies sensor, Bloomberg reports 05/24/21 Luminar jumps after Bloomberg reports LiDAR contract with Tesla 05/24/21 Tesla has contract to use Luminar laser-sensors, Bloomberg reports JNJ Johnson & Johnson $164.97 / +1.9 (+1.17%) 11/12/21 Dealreporter sees 3M, Dover as possible break-up candidates after J&J, GE news 11/12/21 Biden to nominate Robert Califf to lead FDA, Politico reports 11/12/21 Johnson & Johnson plans to separate into two companies, WSJ reports 11/10/21 J&J granted freeze on 38,000 baby powder suits amid bankruptcy, Bloomberg says HPE HP Enterprise $14.66 / -1.28 (-8.03%) 09/30/21 CA court dismisses Oracle's appeal in HP Enterprise Itanium case, Register says 05/17/21 BofA buying of HP Enterprise keeps stock on activist 'radar,' Dealreporter says GE General Electric $107.53 / +0.555 (+0.52%) 11/12/21 General Electric's spin off power business to face competition, WSJ reports 10/19/21 General Electric mandates COVID-19 shot for U.S. workers, Reuters says 09/30/21 General Electric, Siemens resolve gas turbine trade secret fight, Bloomberg says FB Facebook; also tag MVRS $340.00 / +12.27 (+3.74%) 11/10/21 Microsoft to integrate Teams into Meta's Workplace platform, The Verge reports 11/10/21 Facebook internal research shows platform lets stolen content thrive, WSJ report 11/09/21 EU policy makers seek to act quickly to regulate social media, WSJ reports 11/05/21 Meta says 'WSJ report ignores our approach to well-being research' CZR Caesars $106.10 / +4.155 (+4.08%) 11/08/21 NYSGC awards nine temporary mobile sports betting licenses, NY Sports Day says 09/03/21 888, Apollo vying to buy William Hill European ops from Caesars, Bloomberg says 08/27/21 ESPN seeks over $3B sports-betting license deal, WSJ reports CPNG Coupang $26.60 / -2.575 (-8.83%) 10/27/21 SoftBank fund borrows against DoorDash, Coupang stakes, Bloomberg says 10/27/21 DoorDash, Coupang stakes used to back SoftBank fund borrowings, Bloomberg says 09/08/21 South Korea warns internet companies of abusing market dominance, Bloomberg says 06/17/21 eBay set to sell South Korea business for $3.1B, FT reports CONE CyrusOne $85.23 / +2.51 (+3.03%) 11/12/21 CyrusOne in advanced takeover talks with private equity, WSJ reports 11/12/21 CyrusOne near sale to private equity with value over $10B, WSJ reports 09/28/21 CyrusOne exploring alternatives including potential sale, Reuters reports 09/28/21 CyrusOne working with bankers to explore possible sale, Reuters reports CGEN Compugen $5.84 / -1.32 (-18.44%) 06/14/21 Compugen may see partnership interest after iTeos deal, Dealreporter says BLNK Blink Charging $39.98 / +4.42 (+12.43%) 11/07/21 EV charging stations win jolt of energy in Congress, WSJ says BKNG Booking Holdings $2,453.11 / -23.96 (-0.97%) 07/24/21 Tripadvisor the cheapest online travel stock, good time to buy, Barron's says AZN AstraZeneca $58.87 / -4.03 (-6.41%) 11/09/21 AstraZeneca forms vaccines division for COVID-19 assets, Bloomberg says 11/03/21 Democrats reach agreement to lower prescription prices, WSJ reports 10/28/21 Up to 50M doses of J&J vaccine sitting idle in Emergent plant, Reuters reports AMD AMD $147.96 / +2 (+1.37%) 11/12/21 AMD, Xilinx merger odds get 'boost' as MIIT signals support, Capitol Forum says 10/25/21 AMD to adopt TSMC's new SoIC in HPC chips, DigiTimes reports 09/28/21 AMD CEO sees chip shortage 'less severe' in 2H22, CNBC reports XLNX WRBY SRNE SMAR RIVN RIDE PENN PAGS NVDA JNJ JAMF HYZN HPE HEPS GE FLUX FB CZR CPNG CONE BLNK BKNG BKKT AZN XLNX Xilinx $213.52 / +4.69 (+2.25%) 11/01/21 Northland downgrades AMD on slowing growth, upgrades Intel on foundry chances WRBY Warby Parker $58.38 / +4.905 (+9.17%) 10/25/21 Wall Street in Fives - Must Read Lists for Monday 10/25/21 Wall Street in Fives - Must Read Lists at Midday SRNE Sorrento Therapeutics $6.42 / +0.045 (+0.71%) 08/19/21 Fly Intel: After-Hours Movers SMAR Smartsheet $72.69 / +4.18 (+6.10%) 09/07/21 Fly Intel: After-Hours Movers 08/19/21 Wall Street in Fives - Must Read Lists for Thursday 08/19/21 Wall Street in Fives - Must Read Lists at Midday RIVN Rivian Automotive $129.36 / +6.52 (+5.31%) 11/11/21 Fly Intel: Pre-market Movers RIDE Lordstown Motors $5.67 / -1.235 (-17.90%) 11/12/21 Nvidia, Lordstown downgrades among today's top calls on Wall Street 11/11/21 Fly Intel: After-Hours Movers PENN Penn National $58.32 / +0.12 (+0.21%) 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Bet On It: Penn National feels wrath of earnings miss, Business Insider article PAGS PagSeguro Digital $35.40 / +1.38 (+4.06%) 10/27/21 Wall Street in Fives - Must Read Lists for Wednesday 10/27/21 Wall Street in Fives - Must Read Lists at Midday 10/27/21 Viceroy short two Brazilian payment processors after FBI raids Pax Global NVDA Nvidia $303.98 / +0.14 (+0.05%) 11/12/21 Crypto Currents: Twitter to launch dedicated crypto team JNJ Johnson & Johnson $164.97 / +1.9 (+1.17%) 11/12/21 Wall Street in Fives - Must Read Lists at Midday 11/12/21 Fly Intel: Pre-market Movers 11/10/21 Wall Street in Fives - Must Read Lists for Wednesday 11/02/21 Wall Street in Fives - Must Read Lists for Tuesday JAMF Jamf Holding $32.49 / -8.77 (-21.26%) 08/23/21 Wall Street in Fives - Must Read Lists for Monday HYZN Hyzon Motors $7.17 / +0.875 (+13.90%) 10/05/21 Wall Street in Fives - Must Read Lists for Tuesday 10/05/21 Wall Street in Fives - Must Read Lists at Midday HPE HP Enterprise $14.66 / -1.28 (-8.03%) 09/30/21 Wall Street in Fives - Must Read Lists for Thursday 09/30/21 Wall Street in Fives - Must Read Lists at Midday 09/03/21 Wall Street in Fives - Must Read Lists for Friday HEPS Hepsiburada $3.56 / -2.06 (-36.65%) 07/24/21 Opening Day: Zoom Video rival Kaltura rises in market debut 07/03/21 Opening Day: DiDi pops, then drops, after anticipated debut GE General Electric $107.53 / +0.555 (+0.52%) 11/09/21 Wall Street in Fives - Must Read Lists for Tuesday 11/09/21 Wall Street in Fives - Must Read Lists at Midday FLUX Flux Power $6.14 / +0.03 (+0.49%) 10/05/21 Lordstown, Albertsons cut to sell in today's top calls on Wall Street FB Facebook; also tag MVRS $340.00 / +12.27 (+3.74%) 11/10/21 #SocialStocks: EU eyes tech legislation in first half of 2022 11/08/21 Wall Street in Fives - Must Read Lists for Monday CZR Caesars $106.10 / +4.155 (+4.08%) 11/02/21 Fly Intel: After-Hours Movers CPNG Coupang $26.60 / -2.575 (-8.83%) 08/12/21 Wall Street in Fives - Must Read Lists for Thursday 08/12/21 Wall Street in Fives - Must Read Lists at Midday 08/12/21 Fly Intel: Pre-market Movers CONE CyrusOne $85.23 / +2.51 (+3.03%) 09/28/21 Wall Street in Fives - Must Read Lists for Tuesday 07/29/21 Wall Street in Fives - Must Read Lists for Thursday 07/29/21 Wall Street in Fives - Must Read Lists at Midday BLNK Blink Charging $39.98 / +4.42 (+12.43%) 11/08/21 Charged: Workhorse being investigated by DOJ, Rivian to go public this week BKNG Booking Holdings $2,453.11 / -23.96 (-0.97%) 11/10/21 Wall Street in Fives - Must Read Lists at Midday 11/10/21 GE, Booking Holdings upgrades among today's top calls on Wall Street BKKT Bakkt $24.43 / -1.75 (-6.68%) 11/05/21 Crypto Currents: Marathon, Riot, CleanSpark report October bitcoin production 10/29/21 Crypto Currents: Mastercard, Bakkt partner for crypto solutions AZN AstraZeneca $58.87 / -4.03 (-6.41%) 10/15/21 Wall Street in Fives - Must Read Lists for Friday 10/08/21 Fly Intel: Pre-market Movers 11/18/21 Healthcare 11/12/21 SITC 2021 11/15/21 The Virtual Liver Meeting 2021 11/16/21 2021 Virtual Healthcare Conference 11/17/21 Depositary Receipts Virtual Investor Conference 11/18/21 London Healthcare Virtual Conference 2021 11/30/21 25th Annual Technology, Media & Telecom Conference 11/30/21 4th Annual HealthCONx Conference 12/01/21 45th Nasdaq Virtual Investor Conference 12/06/21 Global TMT Virtual Conference 11/12/21 AstraZeneca - AZN 11/12/21 Warby Parker - WRBY 11/12/21 New Gold - NGD 11/12/21 Hyzon Motors - HYZN 11/12/21 Compugen - CGEN 11/12/21 Bakkt - BKKT 11/12/21 Flux Power - FLUX 11/17/21 Nvidia - NVDA 11/29/21 Compugen - CGEN 01/25/22 Johnson & Johnson - JNJ 11/13/21 Compugen 11/15/21 Sorrento Therapeutics, Inc. 11/18/21 Johnson & Johnson 12/02/21 Jamf Holding XLNX WRBY SRNE SMAR RIDE PENN PAGS NVDA MAPS LAZR JNJ HYZN HPE GE FB CZR CPNG BLNK BKNG BKKT AZN AMD XLNX Xilinx $213.52 / +4.69 (+2.25%) 11/09/21 Xilinx put volume heavy and directionally bearish 10/27/21 Early notable gainers among liquid option names on October 27th 10/13/21 Early notable gainers among liquid option names on October 13th WRBY Warby Parker $58.38 / +4.905 (+9.17%) 11/02/21 Three new option listings and five option delistings on November 2nd SRNE Sorrento Therapeutics $6.42 / +0.045 (+0.71%) 11/05/21 Sorrento Therapeutics options imply 4.8% move in share price post-earnings 10/27/21 Sorrento Therapeutics call volume above normal and directionally bullish 09/17/21 Sorrento Therapeutics call volume above normal and directionally bullish 08/09/21 Sorrento Therapeutics call volume above normal and directionally bullish SMAR Smartsheet $72.69 / +4.18 (+6.10%) 09/07/21 Smartsheet options imply 14.0% move in share price post-earnings RIDE Lordstown Motors $5.67 / -1.235 (-17.90%) 11/11/21 Lordstown Motors call volume above normal and directionally bullish 11/11/21 Unusually active option classes on open November 11th 10/28/21 Lordstown Motors call volume above normal and directionally bullish 10/26/21 Lordstown Motors call volume above normal and directionally bullish PENN Penn National $58.32 / +0.12 (+0.21%) 11/04/21 Post-earnings opening call buyer in Penn Gaming 11/04/21 Unusually active option classes on open November 4th 10/19/21 Early notable gainers among liquid option names on October 19th PAGS PagSeguro Digital $35.40 / +1.38 (+4.06%) 07/19/21 PagSeguro Digital put volume heavy and directionally bearish 06/02/21 PagSeguro Digital options imply 8.8% move in share price post-earnings NVDA Nvidia $303.98 / +0.14 (+0.05%) 11/08/21 NVIDIA put buyer realizes 11% same-day gains 11/05/21 Notable open interest changes for November 5th 11/05/21 Unusual call flow in option market yesterday 11/04/21 Call trading frenzy in Nvidia as shares lift 10% MAPS WM Technology $9.50 / -2.12 (-18.24%) 10/14/21 Largest borrow rate increases among liquid names 08/19/21 Largest borrow rate increases among liquid names 06/17/21 Largest borrow rate increases among liquid names 06/16/21 Seven new option listings and two option delistings on June 16th LAZR Luminar $19.59 / -0.4 (-2.00%) 11/09/21 Unusually active option classes on open November 9th 10/26/21 Luminar Technologies call volume above normal and directionally bullish 10/13/21 Luminar Technologies call volume above normal and directionally bullish 10/13/21 Unusually active option classes on open October 13th JNJ Johnson & Johnson $164.97 / +1.9 (+1.17%) 11/12/21 Unusually active option classes on open November 12th 10/28/21 Johnson & Johnson call volume above normal and directionally bullish 10/19/21 Unusually active option classes on open October 19th 09/28/21 Johnson & Johnson call volume above normal and directionally bullish HYZN Hyzon Motors $7.17 / +0.875 (+13.90%) 10/25/21 Largest borrow rate increases among liquid names 10/04/21 Largest borrow rate increases among liquid names 09/29/21 Hyzon Motors call volume above normal and directionally bullish 09/08/21 Largest borrow rate increases among liquid names HPE HP Enterprise $14.66 / -1.28 (-8.03%) 09/30/21 Hewlett Packard Enterprise call volume above normal and directionally bullish 09/30/21 Early notable gainers among liquid option names on September 30th 09/03/21 Early notable gainers among liquid option names on September 3rd 09/02/21 Hewlett Packard Enterprise options imply 4.7% move in share price post-earnings GE General Electric $107.53 / +0.555 (+0.52%) 11/09/21 Early notable gainers among liquid option names on November 9th 10/26/21 Early notable gainers among liquid option names on October 26th 07/28/21 Notable open interest changes for July 28th 07/27/21 Early notable gainers among liquid option names on July 27th FB Facebook; also tag MVRS $340.00 / +12.27 (+3.74%) 10/27/21 Notable open interest changes for October 27th 10/26/21 Notable open interest changes for October 26th 10/25/21 Facebook options imply 9.3% move in share price post-earnings 10/25/21 Notable open interest changes for October 25th CZR Caesars $106.10 / +4.155 (+4.08%) 11/12/21 Early notable gainers among liquid option names on November 12th 09/17/21 Early notable gainers among liquid option names on September 17th 08/26/21 Early notable gainers among liquid option names on August 26th 08/25/21 Early notable gainers among liquid option names on August 25th CPNG Coupang $26.60 / -2.575 (-8.83%) 08/25/21 Largest borrow rate increases among liquid names 08/11/21 Coupang options imply 17.9% move in share price post-earnings 07/27/21 Largest borrow rate increases among liquid names BLNK Blink Charging $39.98 / +4.42 (+12.43%) 11/08/21 Blink Charging call volume above normal and directionally bullish 11/08/21 Unusually active option classes on open November 8th 11/01/21 Unusually active option classes on open November 1st 10/28/21 Blink Charging call volume above normal and directionally bullish BKNG Booking Holdings $2,453.11 / -23.96 (-0.97%) 08/05/21 Early notable gainers among liquid option names on August 5th BKKT Bakkt $24.43 / -1.75 (-6.68%) 11/11/21 Largest borrow rate increases among liquid names 11/10/21 Largest borrow rate increases among liquid names 10/29/21 VPC Impact Acquisition Holdings call volume above normal and directionally bullish 10/25/21 Unusually active option classes on open October 25th AZN AstraZeneca $58.87 / -4.03 (-6.41%) 11/12/21 AstraZeneca put volume heavy and directionally bearish 11/01/21 AstraZeneca put volume heavy and directionally bearish 09/24/21 AstraZeneca call volume above normal and directionally bullish AMD AMD $147.96 / +2 (+1.37%) 11/12/21 Notable open interest changes for November 12th 11/09/21 Notable open interest changes for November 9th 11/05/21 Advanced Micro call buyer realizes 177% same-day gains

On The Fly

News and insights, exclusive to thefly.com

14:14	Fly Intel: What to watch in Netflix earnings report»
12:23	Wall Street in Fives - Must Read Lists at Midday»
10:08	Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations»
08:59	Fly Intel: Pre-market Movers»
19:14	Fly Intel: After-Hours Movers»

View all On The Fly Stories »

Upcoming
Events (10)

RTOKY	Rentokil - RTOKY
KNRLF	Kontrol Technologies - KNRLF
TMX	Terminix - TMX
	ASEAN Disruptive Growth Virtual Conference
	China Renewable Energy Day
BTBT ...	Winter Virtual Small Cap Conference
	The Biden Administration’s FDA: What to Expect in 2022
AGN ...	Octane Aesthetics Tech Summit 2022
	China Consumer Virtual Corporate Days
IMCC ...	KCSA Cannabis Investor Virtual Conference

View all of today’s events »

Today’s
Syndicate (5)

FSPR	IPO
RHDM	IPO
STRR	Secondary
AMH	Spot Secondary
EVA	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial